

# **Ank3 (Epithelial Ankyrin), a Widely Distributed New Member of the Ankyrin Gene Family and the Major Ankyrin in Kidney, Is Expressed in Alternatively Spliced Forms, Including Forms That Lack the Repeat Domain**

Luanne L. Peters,\* Kathryn M. John,\* Frederick M. Lu,\* Eva M. Eicher,† Ann Higgins,‡ Maria Yialamas,\* L. Christine Turtzo,\* Anthony J. Otsuka,§ and Samuel E. Lux\*

\*The Division of Hematology/Oncology, Children's Hospital and the Dana Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115; †The Jackson Laboratory, Bar Harbor, Maine 04609; and ‡Department of Biological Sciences, Illinois State University, Normal, Illinois 61790

**Abstract.** We cloned a novel ankyrin, Ank3, from mouse kidney cDNA. The full-length transcript is predicted to encode a 214-kD protein containing an 89 kD, NH<sub>2</sub> terminal "repeat" domain; a 65 kD, central "spectrin-binding" domain; and a 56 kD, COOH-terminal "regulatory" domain. The *Ank3* gene maps to mouse Chromosome 10, ~36 cM from the centromere, a locus distinct from *Ank1* and *Ank2*.

Ank3 is the major kidney ankyrin. Multiple transcripts of approximately 7.5, 6.9, 6.3, 5.7, 5.1, and 4.6 kb are highly expressed in kidney where *Ank1* and *Ank2* mRNAs are barely detectable. The smaller mRNAs ( $\leq 6.3$  kb) lack the entire repeat domain. These transcripts have a unique 5' untranslated region and NH<sub>2</sub>-terminal sequence and encode a predicted protein of 121 kD. Two small sequences of 21 and 18 amino acids are alternatively spliced at the junction of the repeat and spectrin-binding domains in the larger ( $\geq 6.9$  kb) RNAs. Alternative splicing of a 588 bp sequence (corresponding to a 21.5-kD acidic amino acid sequence) within the regulatory domain also occurs.

Ank3 is much more widely expressed than previously

described ankyrins. By Northern hybridization or immunocytochemistry, it is present in most epithelial cells, in neuronal axons, in muscle cells, and in megakaryocytes/platelets, macrophages, and the interstitial cells of Leydig (testis). On immunoblots, an antibody raised to a unique region of the regulatory domain detects multiple Ank3 isoforms in the kidney (215, 200, 170, 120, 105 kD) and in other tissues. The 215/200 kD and 120/105-kD kidney proteins are close to the sizes predicted for the 7.5/6.9- and 6.3/5.7-kb RNAs (with/without the 588-bp acidic insert). Interestingly, it appears that Ank3 exhibits a polarized distribution only in tissues that express the ~7.0-kb isoforms, the only isoforms in the kidney that contain the repeat domain. In tissues where smaller transcripts ( $\leq 6.3$  kb) are expressed, Ank3 is diffusely distributed in some or all cells and may be associated with cytoplasmic structures.

We conclude that Ank3 is a broadly distributed epithelial ankyrin and is the major ankyrin in the kidney and other tissues, where it plays an important role in the polarized distribution of many integral membrane proteins.

**T**HE ankyrins are a family of conserved proteins that link integral membrane proteins to the spectrin-based membrane skeleton (reviewed in reference 53). Ankyrins are present in a wide variety of vertebrate cells, and ankyrin-like proteins have been described in primitive organisms such as fruit flies (*Drosophila melanogaster*) (24) and worms (*Caenorhabditis elegans*) (Otsuka, A. J., R. Franco, B. Yang, K-H. Shim, L. Z. Tang, and A. Jeyaprakash. 1991. *J Cell Biol.* 115:465a).

Address all correspondence to S. E. Lux, Div. Hematology/Oncology, Enders 7, Children's Hospital, 300 Longwood Ave., Boston, MA 02115. Tel.: (617) 335-7904. Fax: (617) 335-7262.

K. M. John and F. M. Lu have agreed to share second authorship.

Two vertebrate ankyrin genes have been cloned and sequenced. The first, erythrocyte ankyrin (human gene symbol *ANK1*/mouse gene symbol *Ank1*)<sup>1</sup> is located on chromosome 8 in both humans and mice (41, 45, 46, 64, 65). *Ank1* links the  $\beta$  subunit of spectrin to the cytoplasmic domain of the transmembrane anion exchanger, band 3

1. Nomenclature: In this paper ankyrin genes are indicated by their assigned genetic symbols: *ANK1*, *ANK2*, etc. (human genes) and *Ank1*, *Ank2*, etc. (mouse genes) (53). The corresponding proteins are *Ank1*, *Ank2*, etc. *Ank1* is also called erythrocyte ankyrin or ankyrin<sub>R</sub>, and *Ank2* is called brain ankyrin or ankyrin<sub>B</sub> (12). Ankyrin<sub>C</sub>, a novel ankyrin localized to axons (37) is an isoform of *Ank3*.

(AE1), in the red blood cell (RBC)<sup>2</sup> (7). This interaction is critical to the stability of the RBC membrane; genetic defects in Ank1 can result in severe hemolytic anemia (44, 46, 65). Ank1 is highly expressed not only in erythroid tissues, but also in Purkinje cells and granule cells of the cerebellum, in motor neurons of the spinal column, and in a small subset of neurons in the hippocampus (35, 54). However, it is the second member of the ankyrin gene family, brain ankyrin or Ank2, that is the major form of ankyrin in the nervous system (52). Ank2 is alternatively spliced to form several species, including 220- and 440-kD isoforms (12). In rats, the 220-kD isoform predominates in adults, while the 440-kD isoform is most highly expressed during the neonatal period (12). The 220-kD isoform is broadly distributed in the brain, being present in neuron cell bodies and dendrites and in glia (12, 36). In contrast, the 440-kD

isoform appears to be targeted specifically to unmyelinated axons and dendrites. Its expression decreases coincident with myelination (12). Ank2 is encoded by a gene on human chromosome 4q (62) and mouse Chromosome 3 (54).

Structurally, both Ank1 and Ank2 consist of three domains: an NH<sub>2</sub>-terminal "repeat" domain that binds band 3 (AE1) (16), AE3 (48), tubulin (16), and other proteins; a central "spectrin-binding" domain that binds spectrin and possibly vimentin (18, 28, 55); and a COOH-terminal "regulatory" domain, so-called because it can modulate the binding affinities of the first two domains (19).

The wide tissue distribution of ankyrin immunoreactive proteins and the limited expression of Ank1 and Ank2 transcripts suggest that additional ankyrin genes exist. Here, we report the isolation, cDNA sequence, genetic localization and protein/mRNA distribution of a novel ankyrin, Ank3, in the mouse. Ank3 is the most widely distributed ankyrin. It is the major form of ankyrin in mouse kidney and other epithelial tissues, and it is also expressed in macrophages, megakaryocytes, and Leydig cells; in cardiac, smooth, and skeletal muscle; in the initial segments

2. *Abbreviations used in this paper:* cM, centimorgans; dNTP, deoxynucleotide triphosphates; GCG, Genetics Computer Group; GST, glutathione S transferase; RBC, red blood cell; RFLP, restriction fragment length polymorphism; RT-PCR, reverse transcription-PCR; SSLP, simple sequence length polymorphism; TTBS, Tris-Tween 20 buffered saline.

Table 1. Oligonucleotide Primers

Name	Sequence	Location in Ank3 (bp, 5'→3')
Degenerate oligonucleotides*		
A	5'- <u>GCA</u>   <u>CTAG</u>   <u>TGG</u>   <u>GAA</u>   <u>GAT</u>   <u>ATT</u>   <u>ACI</u>   <u>GGI</u>   <u>ACI</u>   <u>AC-3'</u> A "Q" W E D I T G T T	3822→3850
B	3'- <u>ACA</u>   <u>TAC</u>   <u>TGI</u>   <u>CTA</u>   CTA   <u>TTT</u>   <u>CAG</u>   <u>CTG</u>   <u>TTT</u>   <u>TG-5'</u> G M T D D K V D K T	4081→4053
C	3'- <u>GGI</u>   <u>ATA</u>   <u>TAC</u>   <u>CGI</u>   <u>TTT</u>   <u>AA-5'</u> P Y M A K F	4000→3984
D	3'- <u>AAA</u>   <u>TGI</u>   <u>TGI</u>   <u>TTA</u>   <u>CAI</u>   <u>AGI</u>   <u>CGI</u>   <u>GCTT</u>   <u>AAG</u>   <u>ACC-5'</u> G F T T N V S A "R" F W	3911→3882
E2a	5'-CAA   <u>GGT</u>   <u>ACC</u>   <u>ACI</u>   <u>CCI</u>   <u>CTI</u>   <u>CAT</u>   TGG   <u>GC-3'</u> Q G T T P/A L H W A	2091→2116
E2b	5'-CAA   <u>GGT</u>   <u>ACC</u>   <u>ACI</u>   <u>CCI</u>   <u>CTI</u>   <u>CAT</u>   <u>CTI</u>   <u>GC-3'</u> Q G T T P/A L H L A	2091→2116
Other oligonucleotides		
4B	3'-GGTTCTCCTAGGCACACCCAGAGGTCC-5'	3600→3574
19D	5'-CAGAAACGATGAATGAAGTCTCTCGATT-3'	2515→2541
A3REGR1	3'-TATCAGTGGTTCTCACCTCACACCCAGTCGACG-5'	6053→6021
A3REGR2	3'-CAGTCAGGTCTGGTGAACAGTATGACGGTCA-5'	5985→5953
A3REGF1	5'-CACATAAAAAGGCTGAGAAGGCAGACAGACGCC-3'	4372→4404

\*Degenerate oligonucleotides were constructed to match the amino acid sequences shown, with the exception that the 5' end of some oligonucleotides was modified to include a restriction site. Sense oligonucleotides are shown with the 5' end on the left; antisense oligonucleotides have the 5' end on the right. The nucleotides that match sequences in Ank-3 are underlined. The locations of the matching sequences is shown at the right (numbered from the 5' end of Ank3-7kb, Fig. 3). I, deoxyinosine triphosphate.

of axons; and in the nodes of Ranvier (37). *Ank3* is the third distinct member of the ankyrin gene family to be described.

## Materials and Methods

### Preparation of RNA and Northern Blots

Total RNA was isolated by the guanidinium thiocyanate-phenol-chloroform method (13). Polyadenylated RNA (polyA(+)-RNA, also termed mRNA) was isolated by oligo(dT) chromatography (57). For northern blots total RNA or polyA(+)-RNA was separated by denaturing gel electrophoresis, transferred to nylon filters (Zetabind; AMF Cuno, Meriden, CT), and hybridized with <sup>32</sup>P-labeled probes using standard techniques (57). Hybridizations and post-hybridization washes were performed at 42°C and 65°C, respectively, as described (54).

### Primer Sequences and Hybridization Probes

The primer sequences used in PCR and reverse transcription PCR (RT-PCR) experiments described in this study are listed in Table I. The locations of the hybridization probes used to screen cDNA libraries, map *Ank3* by Southern hybridization, and analyze *Ank3* transcripts by northern hybridization are illustrated in Fig. 3.

### Cloning of *Ank3* by RT-PCR

**PCR1.** This RT-PCR product was the initial clone of *Ank3* and was obtained using degenerate oligonucleotide primers A, B, and C (Table I). The cDNA synthesis reaction included (20  $\mu$ l total volume): 1  $\mu$ g mouse polyA(+)-RNA (kidney, brain, thymus), 4  $\mu$ l 5 $\times$  cDNA synthesis buffer (GIBCO BRL Life Technologies, Gaithersburg, MD), 1 mM DTT, 20 U RNasin (Promega Biotec, Madison, WI), 10 pmol of primer B, and 200 U Superscript<sup>TM</sup> RNase H<sup>-</sup> M-MLV reverse transcriptase (GIBCO BRL). The mixture was incubated at 37°C for 60 min and the cDNA-mRNA complex was purified by phenol extraction and ethanol precipitation. The first-strand cDNA was amplified by PCR in a reaction mixture containing (100  $\mu$ l total volume): 10  $\mu$ l 10 $\times$  PCR buffer (Boehringer-Mannheim Biochemicals, Indianapolis, IN), 200  $\mu$ M of each deoxynucleotide triphosphate (dNTP), 100 pmol of degenerate oligonucleotide primers A and B, 5  $\mu$ l (25%) of the first-strand cDNA reaction, and 2.5 U TaqI DNA polymerase (Boehringer-Mannheim Biochemicals). The PCR reaction was conducted for 30 cycles (95°C, 1 min; 65°C, 1.5 min; 72°C, 1.5 min) with a 15-min incubation at 72°C following the last cycle. The RT-PCR reaction yielded a 260-bp product from brain and kidney mRNA that hybridized with an internal oligonucleotide (oligonucleotide C) that was 5' end-labeled with  $\gamma$ -[<sup>32</sup>P]-ATP (3,000 Ci/mmol) and polynucleotide kinase (57). This product (PCR1) was purified from agarose using a Spin-X centrifuge filter (Costar Corp., Cambridge, MA), and subcloned (57) into the Bluescript KSII (+) vector (Stratagene, La Jolla, CA) for sequencing.

**PCR2.** This RT-PCR clone bridged the junction between the repeat and spectrin-binding domains. It was obtained as described above for PCR1. Reverse transcription was primed with primer B and the cDNA was amplified using primer D (representing a conserved sequence in the spectrin-binding domain) and a 1:1 mixture of primers E2a and E2b (which encode several versions of the highly conserved -G-TPLH-A sequence found at the beginning of many ankyrin repeats). The product (1,925 bp) was cut at two internal PstI sites (bps 2,257 and 3,429) and the major fragment (PCR2, ~1.1 kb) was subcloned into Bluescript KSII (+) and sequenced.

**PCR3, PCR4, and PCR5.** These products were obtained by RT-PCR using a single tube assay (63) under the following reaction conditions (25  $\mu$ l total volume): 0.5–1.0  $\mu$ g mRNA, 20 pmol each of oligonucleotides 4B and 19D, 100  $\mu$ M of each dNTP, 2 mM MgCl<sub>2</sub>, 67 mM TrisCl, pH 8.8, 17 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 6 mM Na<sub>2</sub>EDTA, 1 mM DTT, 0.02% gelatin, 2  $\mu$ g yeast tRNA, 20 U RNasin (Promega Biotec), 33 U reverse transcriptase (AMV Super RT; Molecular Genetic Resources, Tampa, FL), and 2.5 U Taq I DNA Polymerase (Boehringer-Mannheim Biochemicals). The cDNA synthesis reaction was carried out for 60 min at 42°C followed by 5 min at 94°C. Subsequent amplification was performed for 30–40 cycles (94°C, 1 min; 60°C, 2 min; 72°C, 2 min) with a 7-min incubation at 72°C following the last cycle. The products (1.0–1.1 kb) were subcloned into the PCR<sup>TM</sup> vector using the TA cloning system (Invitrogen, San Diego, CA) and sequenced.

***Ank3* Regulatory Domain (Including PCR6 and PCR7).** The regulatory domain of *Ank3* was amplified by RT-PCR, using a method designed to amplify large fragments (2), to test for alternatively spliced products, such as those characteristic of the *Ank1* regulatory domain (41, 45). Reverse transcription was performed in a final volume of 20  $\mu$ l containing: 1.4  $\mu$ g total RNA, 500  $\mu$ M each dNTP, 10 mM DTT, 40 U RNasin, 50 mM TrisCl, pH 8.3, 75 mM KCl, 3 mM MgCl<sub>2</sub>, and 400 U M-MLV reverse transcriptase (GIBCO BRL). cDNA synthesis was primed with 1  $\mu$ g oligo-dT (d(pT)<sub>12-18</sub> (Collaborative Biomedical Products, Lexington, MA) or with A3REGR1 (Table I). The mixture was incubated for 120 min at 42°C. Amplification of the first-strand cDNA was performed using a mixture of KlenTaq I and *Pfu* DNA polymerases (2). The reaction mixture (50  $\mu$ l) included: 5  $\mu$ l (25%) of the RT reaction mixture, 20 mM TrisCl, pH 8.75, 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 100  $\mu$ g/ml BSA, 250  $\mu$ M of each dNTP, 125 ng of the appropriate forward and reverse primers (A3REGR2 and A3REGF1, Table I), 11.7 U KlenTaq I (AB Peptides, St Louis, MO), and 0.078 U *Pfu* DNA polymerase (Stratagene). The amplification was performed for 30 cycles (94°C, 15 s; 68°C, 24 min) with a 7-min incubation at 72°C following the last cycle. PCR6 and PCR7 were obtained in this manner and subcloned into the TA vector (Invitrogen) and sequenced.

### cDNA Library Construction and Screening

Oligo(dT) and random primed kidney cDNA was prepared from C57BL/6J mice using the Timesaver cDNA synthesis kit (Pharmacia, Uppsala, Sweden) according to the manufacturer's instructions. Following size selection (~400 bp) and ligation of NotI/EcoRI adaptors, the cDNAs were cloned into the lambda ZAP II vector (Stratagene). The unamplified libraries each contained 460,000 plaques and were 94–98% recombinant. The libraries were initially screened by plaque hybridization (57) of Durulon UV nylon filters (Stratagene) using PCR1 (described in the previous section). Subsequent screenings using PCR2 and an NdeI restriction enzyme fragment of clone pA3-19 (probe 2) were also performed to obtain a complete cDNA sequence. Hybridizations and post-hybridization washes were performed at 65°C, as described (54). Positive lambda Zap II clones were excised *in vivo* with helper virus according to the manufacturer's directions, which generated subclones in the Bluescript SK(+) plasmid.

### DNA Sequencing

Plasmid DNA was prepared by the cetyltrimethylammonium bromide (CTAB) method (3) and sequenced on both strands by the dideoxynucleotide chain termination method, using Sequenase Version 2.0 (United States Biochemicals Corp., Cleveland, OH) according to the manufacturer's directions. 7-Deaza-dGTP was used (Deaza Sequenase Kit; U.S. Biochemicals Corp.) and formamide was included in the gels as needed to alleviate compressions. Synthetic oligonucleotide primers were used to extend all sequences. The data were analyzed using the Genetics Computer Group (GCG) programs (21).

### Genetic Mapping

An MspI restriction fragment length polymorphism (RFLP) was detected between the parental strains of an interspecific backcross ([BALB/cJ  $\times$  CAST/Ei]F<sub>1</sub>  $\times$  BALB/cJ) set. The segregation of this RFLP was followed in 77 progeny by Southern blot analysis (57). In addition, to map *Ank3* relative to SSLP (simple sequence length polymorphism) markers, a Taq I RFLP was typed by Southern blot analysis in 94 progeny from an interspecific backcross involving (C57BL/6J  $\times$  *Mus spretus*)F<sub>1</sub> females mated to *M. spretus* males (56). In both cases the hybridization conditions were identical to those detailed above. The hybridization probe was the *Ank3* PCR1 product.

### Antibody Preparation

**Regulatory Domain Antibodies.** The pGEX-2TK vector (32) was used to generate a 45-kD fusion protein containing the NH<sub>2</sub>-terminal portion of glutathione-S-transferase (GST) and amino acids 1550–1587 and 1784–1905 of the regulatory domain of *Ank3* (amino acids 1588 to 1783 are alternatively spliced and were excluded). This segment of *Ank3* was chosen because it has minimal similarity to *Ank1* and *Ank2*, and no significant homology to other proteins in the GenEMBL, PIR, and SWISSPROT databases. The *Ank3* cDNA inserted into pGEX-2TK was generated by the polymerase chain reaction (see section entitled PCR3, PCR4, and PCR5

above) using the pA3-4 clone (see Fig. 3) as the template DNA. The forward primer (5'-CGGGATCCAACCGGATAGACATTGTAACCTGCTGG-3') included a BamHI site (underlined) and the reverse primer (5'-GGAATTCCTCATTTAGGTGCGTCTTCTATGACAAG-3') included an EcoRI site (underlined) preceded by a stop codon (double underlined). The product was digested, ligated into the vector, and transformed into *E. coli* DH5 $\alpha$  using standard techniques (57). The recombinant protein was expressed and purified as described (32, 55) and injected into two rabbits by standard procedures. The resulting antisera were designated antiAnk3-R1 (rabbit No. 11176A) and antiAnk3-R2 (rabbit No. 11176B). Unless noted, antiAnk3-R1 was used.

**Peptide Antibody.** A peptide (DKCTWFKIPKVQEVL) corresponding to alternatively spliced insert B (see Figs. 3 and 4) at the junction of the repeat and spectrin-binding domains was synthesized by Research Genetics, Inc. (Huntsville, AL) and used to generate an antibody (antiAnk3-B) in rabbits.

### Affinity Purification of Ank3-R1 Antiserum

The Ank3-R1 antiserum was purified by batch adsorption to the GST/Ank3 fusion protein coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia). The protein was coupled to the beads and washed according to the manufacturer's directions. 5 ml of Ank3-R1 antiserum was diluted to 50 ml in 10 mM Tris-HCl (pH 7.5) and mixed gently with 1 ml of GST/Ank3 beads at 4°C overnight. The beads were washed (20 vol 10 mM TrisCl, pH 7.5, then 20 vol of the same buffer plus 500 mM NaCl), and the Ank3-R1 antibodies were eluted with 10 vol 100 mM glycine (pH 2.5). After washing the beads with 10 mM TrisCl (pH 8.8), Ank3-R1 antibodies were further eluted with 10 vol freshly prepared 100 mM triethylamine (pH 11.5). After each elution, the antibodies were neutralized with 1 M TrisCl (pH 8.0). The eluted antibodies were dialyzed overnight at 4°C against PBS containing 0.02% sodium azide.

### Preparation of Crude Membranes and Red Blood Cell Ghosts

Mice were anesthetized with avertin and perfused through the left ventricle with 20 ml cold (4°C) homogenization buffer (0.32 M sucrose, 2  $\mu$ g/ml leupeptin, 2  $\mu$ g/ml aprotinin, 2 mM disodium ethyleneglycol-bis( $\beta$ -aminoethyl ether) *N,N,N',N'*-tetraacetate (Na<sub>2</sub> EGTAA), 1  $\mu$ g/ml pepstatin A, 200  $\mu$ g/ml PMSF). Organs were removed and homogenized by hand at 4°C using a Dounce homogenizer. Nuclei were removed by centrifugation for 5 min at 900 g (4°C), and the crude membrane fraction was collected by centrifugation at 30,000 g for 45 min (4°C). The pellet was dissolved in 20% SDS with one-third volume 4 $\times$  Laemmli buffer (39) and boiled 10 min prior to electrophoresis and/or storage at -20°C.

Hemoglobin-depleted ghosts were prepared by repeated lysis in 5 mM sodium phosphate (pH 8.0) containing 1 mM Na<sub>2</sub>EDTA and 20  $\mu$ g/ml PMSF. The final pellet was dissolved in one-third volume 4 $\times$  Laemmli buffer and boiled 5 min prior to electrophoresis and/or storage at -20°C.

### Immunoblot Analysis

SDS-PAGE was performed using a 5% stacking/10% running gel (39) and prestained molecular weight standards (Bio-Rad Kaleidoscope standards: myosin, 202 kD;  $\beta$ -galactosidase, 133 kD; BSA, 71 kD; carbonic anhydrase, 41.8 kD; soybean trypsin inhibitor, 30.6 kD; lysozyme, 17.8 kD; and aprotinin, 6.9 kD). Separated proteins were transferred in a Bio-Rad Trans Blot SD semi-dry apparatus to Immobilon P membranes (Millipore Corp., Bedford, MA) in 48 mM TrisCl, 39 mM glycine, pH 9.2, with 20% methanol and 0.035% SDS. A portion of each gel was stained with Coomassie blue prior to transfer to verify the integrity of the proteins. Efficiency of transfer was monitored by the transfer of the prestained markers, by staining the gel after transfer, and by staining a portion of the filter with Ponceau S after transfer and prior to blocking. Filters were blocked in 5% BSA in TTBS (10 mM TrisCl, 0.05% Tween-20, 150 mM NaCl, pH 8.0) for a minimum of 1 h, incubated for 1–2 h with primary antibody (diluted 1:500 in TTBS plus 1% BSA), washed two times in TTBS, incubated 1 h with goat anti-rabbit IgG alkaline phosphatase conjugate (Bio-Rad) at a dilution of 1:3,000 in TTBS with 1% BSA, and washed twice in TTBS and once in TTBS without Tween-20. Unless otherwise indicated, when an antibody raised to a GST fusion protein was used, such as antiAnk3-R1 or -R2, staining was performed in the presence of a 200-fold molar excess of purified GST to block any possible reactions with GST-cross-reacting epitopes. Bound antibody was visualized with nitroblue tetrazolium/5-

bromo-4-chloro-3-indolyl phosphate using a commercial kit (Bio-Rad). All incubations were performed at room temperature.


### Immunocytochemistry

Mice were anesthetized with avertin and perfused through the left ventricle with 20 ml Bouin's fixative. Tissues were excised, placed overnight in fresh fixative, and routinely processed to paraffin. For detection of Ank3 protein, sections were deparaffinized and hydrated in Tris buffer (0.2 M TrisCl, pH 7.2), incubated with 1% BSA in the same Tris buffer for 30 min at room temperature, washed in Tris buffer containing 0.1% BSA, and incubated overnight in a humidified chamber at 4°C with affinity purified antiAnk3-R1 diluted in Tris buffer containing 0.1% BSA. Control slides were incubated in buffer alone. The following day, the slides were washed in Tris buffer containing "Super Block" (Scytek Laboratories, Logan, UT) at a final dilution of 1:30. Bound antiAnk3-R1 was subsequently detected using a commercial kit (Kirkegaard and Perry Inc., Gaithersburg, MD) according to the manufacturer's directions. Briefly, the slides were incubated for 45 min at room temperature with biotinylated anti rabbit IgG, washed in Tris buffer, and incubated for 45 min at 37°C with alkaline phosphatase-conjugated streptavidin. Positive reaction was seen as a red precipitate. The sections were counterstained with hematoxylin.

## Results


### Isolation of a Novel Ankyrin PCR Product

Comparison of amino acid sequences of human Ank1 and Ank2, and mouse Ank1, with the evolutionarily distant unc44, a *C. elegans* ankyrin that functions in axonal guidance, reveals areas of extensive conservation in the distal portions of the spectrin-binding domains. For example, the sequence AQWEDITGTT is perfectly conserved in all four ankyrins and the sequence CMTDDK(V/E)DKT differs at only one amino acid (Fig. 1 a). To identify novel ankyrins, degenerative oligonucleotide primers correspond-



**Figure 1.** Cloning of Ank3 cDNA. (a) Comparison of amino acid sequences from a highly conserved region within the spectrin-binding domain of human (*Ank1*) and mouse (*Ank-1*) erythrocyte ankyrin, human brain ankyrin (*Ank2*), and *C. elegans* ankyrin (*unc44*). The amino acid numbers refer to the sequence of Ank3. The arrows indicate sequences to which forward (A) and reverse (B) degenerate oligonucleotide primers were designed for amplification of reverse transcribed mouse cDNA. The cDNA synthesis was primed with B and amplified, by PCR, with A and B as primers. The resulting products were then screened by Southern hybridization using C, another degenerate oligonucleotide. (b) Sequence of the single, novel 260-bp ankyrin-related PCR product (*Ank-3*) isolated from mouse kidney using the above strategy.





**Figure 2.** Chromosomal localization of *Ank3* in the mouse. *Ank3* was mapped using an interspecific ([BALB/cJ × CAST/Ei]<sub>F1</sub> × BALB/cJ) backcross set. The segregation of loci (listed at left in descending order from the centromere) in 77 backcross progeny is summarized in the diagram. Open boxes indicate BALB/cJ alleles; filled boxes indicate CAST/Ei alleles. The number of progeny that inherited each type of chromosome is shown at the bottom. Map distances between loci (given as percent recombination ± SE) are shown at the right. The fewest recombinations (4/77) occurred between *Ank3* and the *Amh* (anti-Müllerian hormone) gene. The data place *Ank3* on chromosome 10, 5.2 ± 2.9 map units proximal to *Amh*. Additional gene symbols: *Zfa*, zinc finger protein, autosomal; *Pah*, phenylalanine hydroxylase; *Mgf*, mast cell growth factor; *pg*, pygmy.

ing to these sequences were designed (A and B, Table I) and used in PCR amplification of cDNA reverse transcribed from mouse kidney, brain, spleen, and thymus mRNA. *Ank1* was recovered in abundance from the spleen and to a lesser extent from brain and thymus. It was not detectable in kidney (data not shown). *Ank2* was abundant in brain and detectable in kidney and thymus, but was not recovered from spleen. In addition, a 260-bp product, called PCR1, was obtained from kidney, brain, and thymus RNA. It was the predominant ankyrin isoform in kidney (data not shown). PCR1 showed 61% and 76% amino acid identity to the corresponding regions of *Ank1*


and *Ank2*, respectively (Fig. 1 b). We designated this apparent novel ankyrin *Ank3* (gene symbol *Ank3*).

### *Ank3* Is Located on Chromosome 10

To prove that *Ank3* is encoded by a gene distinct from *Ank1* (mouse Chromosome 8) and *Ank2* (mouse Chromosome 3), we genetically mapped *Ank3* in the mouse using an interspecific backcross ([BALB/cJ × CAST/Ei]<sub>F1</sub> × BALB/cJ) panel. Analysis of the segregation of an *Msp* I restriction fragment length polymorphism in 77 progeny localized *Ank3* to Chromosome 10. The gene order and map distances (given as percent recombination ± SE) are shown in Fig. 2. Based on the consensus map in the mouse (1), *Ank3* is ~36 centimorgans (cM) from the centromere. From these data, we conclude that the ankyrin gene family in the mouse is comprised of at least three distinct genes located on three different chromosomes.

We also mapped *Ank3* relative to SSLP markers using a (C57BL/6J × *Mus spretus*)<sub>F1</sub> × *M. spretus* interspecific backcross set (56). The typing data obtained in this panel have been deposited in the Mouse Genome Database (accession No. MGD-CREX-228) and can be accessed through the World Wide Web (<http://www.jax.org>). No recombinations occurred between *Ank3* and the marker *D10Bir10*, confirming that *Ank3* is on mouse Chromosome 10. The gene order (from the centromere) and map distances (given as % recombination ± SE, in order) are: *D10Bir6* - 8.6 ± 2.9 - *Egr2*, *D10Mit15* - 1.1 ± 1.1 - *D10Bir10*, **Ank3** - 14.3 ± 3.8 - *D10Mit11*.<sup>3</sup> The position of the SSLP marker *D10Mit15* is estimated to be at ~31

3. Gene names and symbols (1) are: *D10Bir6*, DNA segment, Chromosome 10, Birkenmeier (Bir)-6; *Egr2*, Early growth response 2; *D10Mit15*, DNA segment, Massachusetts Institute of Technology (Mit)-15; *D10Bir10*, DNA segment, Chromosome 10, Bir-10; *D10Mit11*, DNA segment, Chromosome 10, Mit-11.



**Figure 3.** Cloning and organization of mouse *Ank3*. (a, CLONES) The organization of relevant *Ank3* cDNA clones obtained by library screening (pA3-1, -2, -3, -4, -8, -13, -15, -19, -26, and -29) or by the polymerase chain reaction (PCR1-7) are shown. Solid lines indicate the portions of each clone/PCR product sequenced on both strands. All cDNA clones except pA3-1, pA3-3, and pA3-8 were completely sequenced. cDNA clones pA3-2 and pA3-29 contain potential translation start sites (arrows). (b, cDNA): The deduced organization of *Ank3* cDNAs. Alternative splice and start sites are indicated. Restriction enzyme sites are marked above the cDNA schematic: A, AccI; B, BamHI; C, ClaI; E, EcoRI; H, Hind III; K, KpnI; N, NdeI; S, SpeI; X, XhoI. The nucleotides at the beginning and end of major domains and the postulated translation start sites are numbered below the schematic. Hybridization probes described in the text are represented by filled boxes 1-4. (c, PROTEIN) The postulated domain structure of mouse *Ank3* protein. Each domain and alternatively spliced isoform is indicated, with the amino acid numbers given above. The 24 repeats of the repeat domain are also shown. Sequences used to generate antibodies to the regulatory domain (*Ank3-R1*) and insert B (*Ank3-B*) are marked at the bottom.

amino acid numbers given above. The 24 repeats of the repeat domain are also shown. Sequences used to generate antibodies to the regulatory domain (*Ank3-R1*) and insert B (*Ank3-B*) are marked at the bottom.

a ANK3-7KB

GGGAACACGGAAAGGTGATCTCTGCTGCTCACTCCCTGATCTCAAGGAAAGATGA 60  
M S 2  
GTGAAGGCCAAGGAGAAGCCCGCAAGCCTGCTCATAGGAAGGAAAGGAAAGAAAT 120  
E E P K E K P A K P A H R K R K G K K S 22  
CTGATGCCAACCGAAGTACTTAAGAGCAGCTCGGGCAGGSCACTGGAAGGCCCTTG 180  
D A N A S Y L R A A R A G H L E K A L D 42  
ACTACATCAAAATGGAGTGGACGTCAACATCTGTAACCAAGATGGATTGAATGCATCC 240  
Y I K N G V D V N I C N O N G L N A L H 62  
ATCTTGCTTCAAAAGAGCCATGGAGTGGTCTCTGAGCTGCTGACAGGGGAAGCCA 300  
L A S K E G H V E V V S E L L O R E A N 82  
ATGTTGATGCCACAAAGAAAGCAACCGCCTTACACATCGCATCTTTGGCTGGCC 360  
V D A A A T K K G N T A L H I A S L A G A 102  
AAGCGGAAGTGGTCAAGCTTTGGTACGAACAGGAAATGTCACGCAACATCTCAGA 420  
A F V V K V L V T N G A N V N A O S O N 122  
ATGGCTTACACCAATGTATATGGCAGCCAGGAGAACCTGGAAAGTCTGAGTTC 480  
G F T P L V M A A O E N H L E V V R F L 142  
TTCTGGCAATGGCCGCAAGCCTGGCCAGGAGCGGCTTACGCCATTCGGCCG 540  
L D N G A S O S L A T E D G F T P L A V 162  
TGGCTCTGCAACAAGTCAATGCAAGTCTGCTCCCTGCTGCGAGAACGACGAAG 600  
A L Q O G H D O V V S L L L E N D T K G 182  
GAAAATGGCCCTCCAGCCCTCCACATCGCAGCCCGAAAGACGACACCAAGGACGAC 660  
K W R L P A L H I A T A R K A A R A A 202  
CTCTGCTCTGCAAGTACACAAACCGGCGAGTGGAGTCAAAGAGTGGCTTACCCCGC 720  
L W L O N D T N A D V F S K S G F T P L 222  
TCCACATAGTCCCACTGGAACATCAATGTGGCCACGTTGCTGTAACCGGAGCG 780  
H T A A H W G N I N V A T L V L N R A A 242  
CTGCTGGACTTACCCGCAAGGATGACATCACTCCCTTACACGTTGCTCGAAGCGAG 840  
A W D F T A R N D T T P L H V A S K R G 262  
GAAATGCAAAATAGTGAAGTATTGCTGGACCGGGTGGCAAGATCGATGCAAGACCA 900  
N A N M V K L A T D R G A K T D A K T R 282  
GGGACGCTGACTCCGTTGCATGTGGGGGAGAAAGTGGCCATGACAGGTGGTAGAGA 960  
D G L T P L H C G A R S G H E O V V E M 302  
TGTTGCTGACAGATCCCGCCATCTTCAAAAACCAAGATGGATTGTCGCACTG 1020  
L W D R S A P I L S K T K N G L S P L H 322  
ACATGGCCACAAAGGAGACATTTAACTCGCTCAACTCCTCCAGCACAACTGC 1080  
M A T O G D H L N C V O L L W O H N V P 342  
CCGTGGACGAGTCAACAGGACTACCTGACTGCCCTCCATGGCTGCCACGCGGCC 1140  
V D D V T N D Y L T A L H W A A H C I G G 362  
ATTACAAAGTGGCAAGTCTTTGGATAGAAAGCTAGCCCAATGCCAAAGCCCTGA 1200  
Y K V A K V L L D K K A S P N A K A L N 382  
ATGGCTTACCCCTTCCATATCGCTGCAAAAAGACCGCATCCGAGTAATGGAACTCC 1260  
G F T P L H I A R L G K A I R V M L L L 402  
TTTTGAGCAGGTCATCTAATCAAGCCGTAACCGAGTGGCCCTTACCCCAATCCATG 1320  
L K H G A S T O A V T E S G L T P I H V 422  
TTGCTGCCCTTACGGGACATTAATATCGGTGACAGCTAATGCATCATGGAGCTCC 1380  
A A F M G H V N T A G L M H H G A S L S P 442  
CAACACCACCAATGTGAGAGGAGACGCGATTGCATATGGCGCTCCGCTCCGCAAG 1440  
N T T N V R G E T A L H M A A R S G O A 462  
CAGAAGTGGTGGTATCTGGTCCAAGATGGGCTCAGGTAGAACAAAAGCTAAGGATG 1500  
E V V R Y L V O D G A Q V E A K A K D D 482  
ACCAGACTCCACTCCATCTCAGCCGACTGGGAAGTGTGACATAGTGAACAACCTGT 1560  
Q T P L H I S A R L G K A D I V O Q H L 502  
TACAGCAAGGAGCATCCCAATGCAGCAAACTTCTGGGTACACCCCTTACCTTG 1620  
Q O G A S P N A A T T S G Y T P L H L A 522  
CGGCCAGAGGGGATGAGGTAGTACGTTCTCTGGATCATGGAGCATTTAT 1680  
A R E G H E D V A A T L D H G A S L S 542  
CCATAACAAGAAAGGATTACCCCTCTGCGAGTGGCAGCAAAATCGGAAAGCTG 1740  
I T T K K G F T P L H V A A K Y G K L E 562  
AAGTCCGAGTCTCTGTCAGAGAGTGGCTCCCGATGCCGAGGAAAGCGGCL 1800  
V A S L L L O K S A T P D A A G K S G G L 582  
TAACTCCACTGCATGTAGCAGCCATACGATAATCAGAAAGTGGCCCTTCTGCTTTGG 1860  
T P L H V A A H Y D N O K V A L L L L D 602  
ACCAGGAGCCTACCCACGAGCGCAAAAGCGCTATACACCACTGCATCTCGCG 1920  
Q G A S P H A A A K N G Y T P L H I T A A 622  
CCAAGAAGACAGATGACATAGCCAGTCCCTGCTGGAGTACGGTCTGATGCAAAAG 1980  
K K N O M D I A S E R L G K A D I V O Q H L 642  
CGTTTACCGCAAGGATTGCTCCGCTCATCTTGGCGCACAGGAGGGCACGTGGACA 2040  
V T R O G I A S V H L A A O E G H V D M 662  
TGTTGCTGCTCTGAGTAGAAGCGGAACTGCAACCTGAGCAATAAGAGCGGCTCA 2100  
V S L L L S R N A N V N L S N K S G G L 682  
CCCACTCCACTGGCTCAAGAAAGCGGATGAATGGCCGAGGTCTTGTCAACC 2160  
P L H L A A O E D R D N V A E V L V N O 702

AGGGGGCCATGTGGATGCTCAGACAAAGTGGCTACACCCCGCTCCATGTGGGCTGTC 2220  
G A H V D A O T K M G Y T P L H V G C H 722  
ACTATGGAAATATCAAAATAGTCAATTTCTGCTGAGCAATCTGCAAAAGTAAATGCCA 2280  
Y G N I K I V N F L L O H S A K V N A K 742  
AGACGAGAATGGATACACAGCAGTGCACAGGCTGCTCAGCAGGGCCACAGCATATCA 2340  
T K N G V T A L H O A A O O G H T H T I 762  
TCAATGTCTGCTCAGAACAGCCCTCCCAATGAATCACTGTGAATGGGAACAG 2400  
N V L L O N N A S P N E L T V N G N T A 782  
CTCTGGCCATCGCCCGGCTTGGTTACATCTCGTGGTTGACACACTGAAGTCTGGA 2460  
L A T A R R R L G V I S V V D T L K V V T 802  
CGGAGAAATATGACCACCACTACCATCCGGAGAACACAAAATGAATGTCCAGAAA 2520  
E E I M T T T T I T E K H K M N V P E T 822  
CGATGAATGAAGTCTCGATATGTCAGAGATGAAGTAAGGAAAGCCAGCCCGGAAA 2580  
M N E V L D M S D D E V R K A S A P E K 842  
AGCTCAGTGGGGAATATATCTCAGAGGCTGAGAGATGTGATBAATGCACATGGTTCA 2640  
L S D G E Y I S D G E E G D K C T K 862  
AATTCCTCAAGTACAGGAGTTTGGTGAATA GTGAAGTGCATCAGAGGGGACACTG 2700  
I P K V O E V L V K S E D A I T G D T D 882  
MEMBRANE DOMAIN ← SPECTRIN DOMAIN  
ACAAGTATCTCGGGCCAGGACTTAAAGACTAGGTGATGACTCCCTCGCCAGCAGAG 2760  
K Y L G P Q D L K E L G D D S L P A E G 902  
GTTACGTAGGCTCAGTCTGGAGCCGTTCTCGCAGCTCCGCTCCTTCAAGTTCGGATA 2820  
Y V G F S L G A R S A S L R S F S S D R 922  
GGCTTACACCTTGAACAGAGCTCCTACGCAAGGACAGCATGATGATGAGGAACCTC 2880  
S Y T L N R S S Y A R D S M M I E E L L 942  
TGTTACCATCAAAAGCAGCAGCTGACGTTGACGAGGAGTTGATTCTGACTCCCTCA 2940  
V P S K E Q H L T F T R E F D S D S L R 962  
GACACTACAGTTGGCAGCGACAGTGTAGATAATGTGAACCTGGCTCAAGCCCGGTGC 3000  
H Y S W A A D T L D N V N L V S S P V H 982  
ATTCTGGTCTTCTGTTAGCTTTATGTTGGAGCGGAGAGGGGCTCCATCGGAGGAA 3060  
S G F L V S F M V D A R G G S M R G S R 1002  
GCCACCAGGGATGGGATCATCATCCTCCCGAAAGTACGGCCCGCCAGCCATCA 3120  
H H G M R I I I P P R K C T A P T R I T 1022  
CGTGGCCGCTGTAAGAGACATAAATCGGCAACCCACCCCATGGTGAAGGAGAG 3180  
C R L V K R H K L A N P P M V E G E G 1042  
GATTAGCCAGTGGTGGTAAAGTGGTCTGGGGGACAAATTTTGGCCCGCTCA 3240  
L A S R L V E M G P A G A Q F L G P V I 1062  
TTGTGAAATCCCTCATTTGGTCCATGAGGGGGAAGAGAGAACTTATCGTCTTC 3300  
V E I P H F G S M R G K E R E L I V L R 1082  
GGAGCGAGACGGAGAGACTGGAAGAACATCAGTTGACAGTAAAACCAAGGAGCCTGC 3360  
S E N G I E T W K E H Q D F S K N E D L A 1102  
CGGAGCTTCTCAATGGCATGGATGAAGACTCGACAGCCCGGAGAGTTGGTACAAGC 3420  
E L L N G M D E E L D S P E E L G T K R 1122  
GCATCTGCAAAATATCAAAAGGATTCCCCAGTATTTGCCGTGGTTTCCCGGATTA 3480  
I C R I I T K D F P Q Y F A V V S R I K 1142  
AGCAGGAAGCAACAGATCGTCTGAGGGTGGGATCTGAGCAGCACCAGCTGCC 3540  
Q E S N Q I G P E G G I L S S T T V P L 1162  
TCGTCCAGGCTCCTCCAGAGGGGCTTAAACAGAGGATCCGTGGGTCTCCAGG 3600  
S E N G I E T W K E H Q D F S K N E D L A 1182  
CTCAGCCGTCAGAGGAAACGGTAAAGAAATCTGGGAAACAAAGCAATTTAGCC 3660  
Q P V P E E T V K K I L G N K A T F S P 1202  
CAATTCAGCGTAGAGCCAGGAGAGGAAATCCATAGCCGATCACCATGACATTC 3720  
I V T V E P R R R R K E H K P I T M T I P 1222  
CGTGGCCCGCTCGGAGAGGCTGTCATAGGTTGGTACAGGGGATGCCAGCCCA 3780  
V P P S G E G V S N G Y K G D A T P N 1242  
ACCTGGGCTCCTGCGATCAGAGGACCTCACCAGCTCAATGGGAGACATCA 3840  
L R L L C S I T G G T S P A Q W E D I T 1262  
CAGGAACAACCCCTGACGTTCAAAAGGATTTGGTCTTCCACAACCAAGCTTTCAG 3900  
G T T L T F I K D C V S T F T C A N V S A 1282  
CCAGATTCTGGCTGGCGACTGCCATCAGGTGTAGAGCCGTAGGGTACGCTCCGAGC 3960  
R F W L A D C H Q V L E T V G L A S Q L 1302  
TGACAGAGGATGATGCGTTCCTACATGKCAAGTTCGTTGTGTTGCCAAAACA 4020  
Y A R E L I C V P Y M A K I T V V F A K T N 1322  
ACGACCCGTTGAGTCTCGCTGAGGTGCTTCTGTATGACAGCAGCAGGGTGGACAAA 4080  
D P V E S S L R C F Q M T D D R V D K T 1342  
CCCTGGAGCAGGAGAACTCGAGAGGTTGCCAGCAAAAGCAATGAGGTTCTGG 4140  
L E Q Q E N F E V A R S K D I E V L E 1362  
AAGAAAGCCATCTACGTTGATGCTAGAACTGGCCCTGACCAAGGAGGAGC 4200  
G K P I Y V D C Y G N L A P L T K G G Q 1382  
AGCAGCTGTTTTAACTTTTCTTTCAAGAAAACAGACTGCCATTTTCCATCAAGA 4260  
Q L V F N E Y S F K E N R L P F S I K I 1402  
TCAGAGACCAAGCAAGCCCTGTCGCGCTGCTTCTCAGGAGGCAAGACAA 4320  
R D T S Q E P C G R L S F L T K A E P K T T 1422  
CAAAGGATTACCCCAACAGCTGTTGCAACTTAAATTAATCTGCGCCACATAAAA 4380  
K G L P Q T A V C N L N I T L P A H K K 1442

AGGCTGAGAAGGCAGACAGCCAGAGCTTTGCTCCCTCA 4440  
 A E K A D R R Q S F A S L A L R K R Y S 1462  
 SPECTRIN DOMAIN ← REGULATORY DOMAIN  
 GCTACTTGACTGAACCAGCATGAGTCCGAGAGTCTTTGAGCGGACGGATATCAGGA 4500  
 Y L T E P S M S P Q S P C E R T D I R M 1482  
 TGGCGATAGTAGCCGATCACCTGGGACTTAGTTGGACAGAGCTGGCAAGGAACTGAAT 4560  
 A I V A D H L G L S W T E L A R E L N F 1502  
 TTTCAGTGGATGAAATCAACCAAATACGTGTGAAAAATCCCAATCTTTAATTTCTCAGA 4620  
 S V D E I N Q I R V E N P N S L I S Q S 1522  
 GCTTCTGTTATTAATAAGTGGGTGACGAGACGGAAAGATGCCAAGCTGATGCTCT 4680  
 F M L L K K R V T R D G K N A T T D A L 1542  
 TAACTTCGCTTAAACGAAGATTAACCGAGATAGACATTGTAACCTGTGGAAGGACCAA 4740  
 T S V L T K I N R I D I V T L L E G P I 1562  
 TATTTGATTATGGGAATATTTGAGGACAGAGCTTTGAGATGAAAAAATGTTTTC 4800  
 F D Y G N I S G T R S F A D E N N V F H 1582  
 ATGACCCAGTTGATG GTCACCTCTCTTCAAGTGGAGCTGGAGACCCCATGGGTTGT 4860  
 D P V D G H P S F O V E L E T P M G L Y 1602  
 ACTGGACACCCCAACCTTTCCAGCAAGATGACCATTTAGTGATATCTCTAGCATAG 4920  
 W T P P N P F O O D D H F S D I S S I E 1622  
 AGTCTCCCTTTAGGACCCCACTGAGTGAAGGCTGGTGCCTTCCAGGAAACA 4980  
 S P F R T P S R L V P R L P S O G N I 1642  
 TAGAGCATCAACAGTGGACCTCCAGTGGTAAACCGCAGAGGACACTCTTTAGAGACA 5040  
 E H P T G G P P V V T A E D T S L E D S 1662  
 GCAAAATGGACGATTCTGTAAGTGAACAGCCCGGACCCACTGGAGCTAGATGAGA 5100  
 K M D P S V T V T D P A D P L D V D E S 1682  
 GCCAGTTGAAGGACTGTGTGAGGAGTGTGTGCTGAGTGGCGAGTGTGCCCGGA 5160  
 Q L K D L C O S E C A O C W A S V P G I 1702  
 TCCCAACGACGGTGGCAGGCGAGCCACTGAGACCCGAGACTAGAAAATAGGCATGA 5220  
 P N D G R Q A E P L R P O T R K V G M S 1722  
 GCTCTGAACAGCAGGAAAAGAAAATCTGGTCTGATGAGGAAGTGAAGAAAGCAAG 5280  
 S E O O E K G K S G P D E E V T E D K Y 1742  
 TCAATCTCTGTTGAGGACATTCAACTGGAAGATGAGGCTGAGGAGATGACAGAAG 5340  
 K S L P F E D I O L E E V E A E E M T E D 1762  
 ACCAGGGGAGGCTGCTTAAACCGTGTGAGCAGGACGAGTGGCAATGCTTCACTG 5400  
 G Q O A M L N R V O R A E L A M S S L A 1782  
 CAG GTTGGCAGAACGAGACGCAAGTGAAGCCTAGAGTCCCAGCGCAAGCTCGAAGAC 5460  
 Q W Q N E T P S G S L E S P A Q A R R L 1802  
 TAACTGGTGGTACTGGACCGTCTGGATGACAGCTCTGACAGGCTCGGGATTCTATTA 5520  
 T G G L L D R L D D S D Q A R D S I T 1822  
 CCTCATACCTCACGGGAGAACTGGGAAGATCGAAGCAATGGAACCACACAGCGGAAG 5580  
 S Y L T G E P P G K I E A N G N H T A E V 1842  
 TCATCCAGAAGCAAAAGCAAAACCTACTCTCCCGAAATCCCAAAACGATATAGGGAAC 5640  
 I P E A K A K P Y F P E S Q N D I G K Q 1862  
 AGAGCATCAAGGAGAACTGAAACCAAAACACCGGATGTGTCGCACTGAGGAACCCAG 5700  
 S I K E N L K P K T H G C R K T E E P V 1882  
 TGTCCCCCTCACAGCCTACCAGAAATCTCTGGAAGAAACAGCAAGCTTGTATAGAAG 5760  
 S P L T A Y Q K S L E E T S K L V I E D 1902  
 ACGCACCTAAACCTGTGTGCTGTGCGCATGAAAAGATGACCAGGACTACGGCTGACG 5820  
 A P K P C V P V G M K M T R T T A D G 1922  
 GCAAGCCAGGCTCAACCTCCAGGAAGAGGGGTCACAGCTCAGAGCTCAAGCAGG 5880  
 K A R L N L Q E E E G S T R S E P K Q G 1942  
 GAGAAGGCTAAGGTGAGAGCAAGAAAGAAATCCGGAACCTGGAGAAGAAACCCACT 5940  
 E G Y K V K T K K E I R N V E K K T H \* 1961  
 AGTGACAGTACGCTCAGTCCAGGACCACTTGGTCACTAGTCCAGTATTGAGAAATCACC 6000  
 AGAGATCAGCAGGAAGAAAAATAGTACCACAGAGTGGAGTGTGGGTGAGTGTCCACC 6060  
 ACACGTGACGACAGATTTTTTTTTTGAACAGCAGAAAGAAACGAAATACATTTT 6120  
 TTCTTTCATTTAGCATGAGCCGATCTCAAAAGATGAAACTCAAAATCATTCGCCGCAC 6180  
 TGAATGCACACTGAGCAAGTGCAGTGTACGACACAGGAAGCCATGTTCTTCCAGCCGG 6240  
 TCTCAAGTAAATTTAGTGCATTTTCAAGAAAGACAGACAAAACACACTGTGCCACCCA 6300  
 GGAGGAGGGCAGCAGAGGACCGAATGATCAAATCAAGAGACACACTAAAATTAATAAA 6360  
 TTCACAACAGCTCGCTTATTTTCTCGGACCAAACTAACTGTGAGGATATAAACAATG 6420  
 TTCCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 6480  
 AATGAAAAAATCAATAGTTTGTGTAAATAATAACACTGTAATTTCTAACAGAAGAAA 6540  
 CTACATAAAGAATTATAAGGCACCCGCTCAGACAACAAAAGATATCACAAATGCATC 6600  
 CAAGGACAGGCTCCCAAGTACTTCCCTGGCAAGGATGGGATCCAGCGCTCTCGG 6660  
 GACTCTTCACTGACTCTGTATATTAGCAATATGTTTGTACGCAAAACTGCTAGCT 6720  
 TGATTTTAAAGAAAAAATGCAAACTTTTAAAGGAAAAAATAAATAAATAAATAAATA 6780  
 CAAATTTAAATAATTTCCCAACAGGAAATCTGTAGTCTGTGAAAAAATTTTTTTT 6840

TCCTCAGAATATAATATTTTGTGATGCATATCACCTTATTTTGAATAATCTTTTCC 6900  
 AATTTTGCAAACTACAGTCTCTGCAACATGGGAGATTTTATCTGTAACACAAAGCC 6960  
 CTCATCTAATATTTATTTGCTATTGCAATTTTCAATGAAATGACCAAAATGAAAAA 7020  
 AAAATAACTATACAGTAGTTTGTCTGGGGTGGGGGGGGGGCGCTGTAGTCTTACAG 7080  
 GGGG 7084

**b ANK3-5KB**

ACTCCTGCTCCCGGCCCTTCTTGTCTCCCTGGGTTGTTTCTTCTACCTGGCT 60  
 TGGTGTCTTCTCATTCACCTTTGAGAAGAGCCCGTCTCCAAATCGCCAGTTACACAAG 120  
 TGCCCGGGCTCTCTGAGCTTGTGAGGTCCTGCTACTCTGACTGCCCTGGTATCAAGT 180  
 TACTGAAAGTCTACACCCAGGAGTCTCATATTTACATACAAATAACTCTGGGTTTGC 240  
 TTTTATGCTACTATTGGTCTGCAAGAGGCTGCCAGAGCTCTTAATCCAATCAGGA 300  
 GGCACCTTTGAAAGGATGTCTGTTGAGCGGTCAGAAGGATGTTCTGCTGCTATAAGTGTG 360  
 CCACACAAAATTTTCGCATGTTTCGGTCTGAGTTTTTTTTTTTTTTTTTAAATCTCG 420  
 GAGTTAAAAAAGTGAGGAATGATGACAGCTGCTGCTGCTGCTGACAGCTGGAGATG 480  
 CTGAGGAAACGCTGACAGCTGTTGAAGAGATGACTAGGGAGGGTTGGATCCAT 540  
 ACCAGGCTGTGTGATTGGGGTGTGTGGACGGCTACTCTAAACCCCTGCTTAAGGA 600  
 ATTCTGGAAGCTCGGGAAGTACTCCCAACAGCTGTGTGAAATGGCTTGGCCAC 660  
 M A L P H 5

ACA gtagaatgccaatcacaggg...  
 S e d a i t g  
 JOINS SPECTRIN DOMAIN

**Figure 4.** Nucleotide sequence, deduced amino acid sequence and postulated domain structure of mouse *Ank3*. (a, *Ank3-7kb*) Amino acids that are identical in human and mouse *Ank1*, human *Ank2*, mouse *Ank3*, and *Drosophila* ankyrin are shaded. The 24 repeats of the repeat domain are underlined and numbered R1-R24. The two small inserts, A and B, at the junction of the repeat and spectrin-binding domains, and the alternatively spliced acidic sequence (insert C) within the regulatory domain are marked with a double underline. The two conserved sequences used to clone *Ank3* (by degenerate oligonucleotide RT-PCR) are underlined with a single line. (b, *Ank3-5kb*) The nucleotide sequence of the 5' untranslated region and first six deduced amino acids of the ~5–6 kb isoforms of *Ank3*, which lack the entire repeat domain. These sequence data are available from EMBL/Genbank/DDBJ under accession numbers L40631 (5-kb isoform) and L40632 (7-kb isoform).

cM on the consensus map (1). Hence *Ank3* is located at ~32 cM on the consensus map using these markers. The data from both backcross sets are therefore in good agreement. *Ank3* is not closely ( $\leq 1$  cM) linked to any mouse Chromosome 10 mutation. Based upon earlier mouse consensus maps, we investigated the possibility that an *Ank3* defect could account for the mocha (gene symbol *mh*) mutation, a mouse platelet storage pool deficiency mutation located on Chromosome 10 (1) (Peters, L. L., E. M. Eicher, K. M. John, T. C. Hoock, M. Yialamas, and S. E. Lux. 1993. *Blood*. 82:340a). However, to date, no defect in the *Ank3* sequence of mocha mice has been found (Peters, L. L., K. M. John, and S. E. Lux, unpublished observations).

**The cDNA Sequence and Predicted Protein Structure of Mouse *Ank3***

We used PCR1 to screen two normal mouse (C57BL/6J-+/+) kidney cDNA libraries. Initially, three positive clones (pA3-1, pA3-2, pA3-4; Fig. 3) were obtained. An additional RT-PCR product, PCR2, was obtained from

kidney using a degenerate forward primer corresponding to conserved sequences at the 3' end of the repeat domains of Ank1 and Ank2 and reverse primers corresponding to conserved sequences in the spectrin-binding domains of Ank1, Ank2, and unc44. Subsequent screenings using PCR2 and the 5' NdeI restriction enzyme fragment of clone pA3-19 (probe 2, Fig. 3) were performed to obtain a complete Ank3 cDNA sequence.

The complete Ank3 cDNA is 7084 nucleotides (Fig. 4 a) and encodes a 1,961-amino acid protein with a predicted mass of 214,144 D and a calculated isoelectric point of 6.68. The postulated translation start site is the first in-frame methionine and is the only start site that yields a structure similar to previous ankyrins.

Like Ank1 and Ank2, Ank3 consists of three domains. The 89-kD NH<sub>2</sub>-terminal "repeat" domain, corresponding to amino acids 1-873, is composed mostly of 24 repeats. Each contains 33 amino acids except for repeat 5, which has only 29. The Ank3 repeat consensus is: -G-T(P/A)LH-AA--G---(V/I)(V/A)--LL---A--(N/D)----. The Ank3 repeats have the characteristic features that distinguish ankyrin repeats from the similar repeats found in many other proteins (10), such as the presence of a hydrophobic amino acid in repeat position No. 3 and an N or D in position No. 29 (53). When the ankyrins are aligned and compared to each other, 19 of the 24 Ank3 repeats are more homologous to the corresponding repeat in Ank2 than in Ank1. Overall the repeat domains of human Ank2 and mouse Ank3 are 76% identical (Fig. 5). Ank3 also shares significant identity to the repeat domain of Ank1 (Fig. 5). The entire domain is conserved except for the first 26 amino acids.

When Ank3 is compared to *Drosophila* ankyrin (24), the identity in the repeat domain falls to 56%. The overall identity is 51%. Hence, not unexpectedly, Ank3 resembles other mammalian ankyrins more than *Drosophila* ankyrin. Despite this, evidence of significant conservation of function between fly and mammalian ankyrins exists. When human Ank1 and Ank2, mouse Ank3, and *Drosophila* ankyrin are compared repeat 1 to repeat 1, repeat 2 to repeat 2, etc., the first 14 repeat positions are all conserved, including some positions (e.g., Nos. 1, 3, 8, 11, and 12) that vary widely from one repeat to the next, while the "variable" positions in the last half of the aligned repeats are not well conserved. Most likely the amino acids in posi-

tions Nos. 1, 3, 8, 11, and 12 have critical functions, such as protein binding, that vary from repeat to repeat. If so, the companion repeats in the various ankyrins must have retained similar functions throughout evolution.

Most of the 65-kD spectrin-binding domain (amino acids 874-1455) is also conserved (Fig. 5), including the basic RRRKFH(K/R) sequence (amino acids 1209-1215) that is required for spectrin-binding in Ank1 (55). (This basic peptide is also present in Ank2 and *Drosophila* ankyrin [24]). Some or all of the first 70 amino acids of the Ank1 spectrin-binding domain are also necessary for full erythroid spectrin-binding capacity (18), but a peptide containing just these amino acids does not bind spectrin, at least not when it is expressed as a fusion protein (55). Interestingly, the first 63 amino acids of the Ank3 spectrin-binding domain are reasonably well conserved compared to Ank2 but differ completely in Ank1 (Fig. 5). This supports the hypothesis (55) that this region is responsible for fine tuning the preferences of ankyrins for spectrin or fodrin (nonerythroid spectrin). Ank2 preferentially binds fodrin, whereas Ank1 favors spectrin (15). The spectrin/fodrin preferences of Ank3 are untested, but judging from where it is expressed (see below) the protein must interact mostly with fodrin. Spectrin binding is thought to be relegated to the first half of the spectrin-binding domain since a 32-40 kD tryptic peptide from that region of Ank1 binds spectrin (55). However, the latter half of the spectrin-binding domain is also well conserved (Fig. 5), suggesting that this region as well serves an important, albeit presently unidentified, binding or modulating function.

The COOH-terminal "regulatory" domain of Ank3 (amino acids 1456-1961), in contrast, is poorly conserved (<30% identical, Fig. 5), except for a segment of unknown function near the beginning of the domain (amino acids 1488-1555), which resembles portions of the cytoplasmic domain of the tumor necrosis factor alpha receptor, and a small segment in insert C (see below). Comparison of Ank1 and Ank2 reveals similar homologous and non-homologous regions (52). *Drosophila* ankyrin shows no significant homology to other ankyrins in the regulatory domain (24).

The GCG program MOTIFS identifies 76 potential phosphorylation sites in Ank3. It is interesting that six of these (at residues 822, 830, 838, 844, 848, and 850) are clustered in or near insert A (see following section) at the




Figure 5. Amino acid homology between the three ankyrins. (Top) Schematic of the domain structure of Ank3. The + marks the location of a basic sequence believed to form part of the spectrin binding site (55). (Bottom) A comparison of the amino acid sequences of mouse Ank1 and human Ank2 with mouse Ank3 reveals extensive homology in the repeat domain and large segments of the spectrin-binding domain. Each point represents the percent identity of 10 aligned amino acids. The highest overall identity is with human Ank2. Notably, sequence conservation is lost at the beginning of the spectrin-binding domain and also falls dramatically in the last two-thirds of the regulatory domain.

junction of the repeat and spectrin-binding domains. This insert is one of the unique features of Ank3 and probably has special binding or regulatory functions.

The complete nucleotide sequence of the Ank3 cDNAs includes a number of alternatively spliced variants and suggests the use of two different start sites. As described later, northern and western blot analyses confirm the existence of multiple Ank3 isoforms.

### ***Ank3 Contains Two Alternatively Spliced Sequences between the Repeat and Spectrin-binding Domains***

The last 13 amino acids of clone pA3-19 are contained within the last 17 amino acids of clone pA3-26. Both differ from PCR2, where an alternative sequence of 18 amino acids is found in the same position (Figs. 3 and 4a). This suggests the presence of at least two small inserts at the 3' end of the repeat domain of Ank3 where it joins the spectrin-binding domain. We designated the partial sequences present in cDNA clones pA3-19 and pA3-26 "insert A" and the 18-amino acid sequence present in PCR2 "insert B", and performed RT-PCR using mouse kidney RNA to amplify these and other sequences across the boundary of the repeat and spectrin-binding domains. Three new products, PCR3, PCR4 and PCR5 were obtained (Fig. 3). Neither insert A nor B is present in PCR3. Insert A alone is present in PCR4, and both inserts are present in PCR5. The complete insert A contains 21 amino acids. We conclude that two inserts are present at the junction of the first two domains of Ank3 and that all four possible splice variants are transcribed in the kidney. It is noteworthy that alternative splicing of Ank1 in the rat brain (40) and mouse cerebellum (9) results in a 24-bp (8 amino acid) insert at precisely the same location as the A and B inserts of Ank3. Although the rat brain and mouse cerebellar inserts (TAHISLTG and TAMISIMG, respectively) resemble one another, there is no homology to Ank3 insert A or B. The functional role of the various inserts at the junction of the repeat and spectrin-binding domains remains to be defined for both Ank1 and Ank3.

### ***Many Ank3 Transcripts Lack the Repeat Domain***

Ank3 clones pA3-2, pA3-13, and pA3-15 lack the repeat domain: a 5' untranslated region is connected directly to the spectrin-binding domain (Fig. 3). To determine if these cDNAs are transcribed, we performed northern analyses of mouse kidney mRNA using domain-specific probes (Fig. 6a, lanes 1 and 2). Probes to sequences within the spectrin-binding (PCR1) and regulatory (probe 1) domains detect two closely migrating mRNAs of 7.5 kb (faint) and 6.9 kb (prominent), one mRNA of 6.3 kb (prominent), a broad band at ~5.7 kb (prominent), which may be heterogeneous, and minor bands of about 5.1 and 4.6 kb (Fig. 6a, lane 2). However, a probe from the Ank3 repeat domain (probe 2) detects only the 6.9 and 7.5 kb mRNAs (Fig. 6a, lane 1), indicating that the smaller transcripts and their encoded proteins lack the repeat domain, as suggested by the cDNA sequences obtained (Fig. 3).

Other data support this conclusion and indicate that at least two translation start sites are utilized in Ank3. For example, the 5' untranslated regions of the cDNA clones that lack a repeat domain (pA3-2, -15, and -13) overlap

and are distinct from the 5' untranslated region attached to the repeat domain (clone pA3-29) (Figs. 3 and 4b). When mouse kidney mRNA is hybridized to a cDNA from the unique 5' untranslated region of the clones lacking the repeat domain (probe 3, the EcoRI fragment of clone pA3-2, in Fig. 3), the 6.3- and 5.7-kb transcripts are strongly labeled, as expected, but at least one 6.9 kb transcript is also marked (Fig. 6a, lane 3). This large transcript must contain sequences that are not present in clones pA-2, -13, -15 and more distal clones (collectively termed "Ank3-5 kb", Fig. 4b) since the Ank3-5-kb sequence is too small. These could be sequences from the repeat domain or other, presently unknown sequences. Similarly, two of the transcripts that are assumed to represent "Ank3-5 kb" are larger (6.3 and 5.7 kb) than the cloned fragments (5.074 kb) and must contain additional sequences.

The only in-frame methionine in this 5' untranslated region adds six new amino acids to the spectrin-binding domain. The surrounding nucleotides only match the consensus sequence of vertebrate translation start sites (38) at positions -6 and +4; however, none of the other positions is statistically rare. There are stop codons in all frames upstream and the next in-frame methionine is 69-amino acids downstream.


### ***Some Ank3 Molecules Contain an Acidic Insert within the Regulatory Domain***

Two major products, PCR6 (1.0 kb) and PCR7 (1.6 kb), were obtained by RT-PCR of the Ank3 regulatory domain (Fig. 3). PCR7 contains an additional sequence of 588 bp (insert C), which appears to correspond to the "2.1 insert" of Ank1 (41, 45). Both inserts are located in the same place in the aligned sequences, both are large (insert C = 21.5 kD, 2.1 insert = 17.3 kD), and both are highly acidic (pI of insert C = 4.0, 2.1 insert = 3.7). However, the sequences are quite different, except for a short segment (Fig. 5, amino acids 1652-1667), and there is only modest conservation of the organization of charged regions and predicted structural elements. Judging from recovered clones (Fig. 3) and from the yield of RT-PCR products, most Ank3 RNA transcripts lack insert C. The difference was not carefully measured but is about threefold. The multiple, COOH-terminal, alternatively spliced products of Ank1 (27) are not observed in Ank3.

Northern blot data confirm that insert C is an alternatively spliced variant that is transcribed in mouse kidney. When kidney mRNA is probed with a sequence from within this exon (probe 4), the 6.9 and 7.5 kb transcripts are observed, and the 6.3 kb and minor 5.1 kb bands remain, but the 5.7 and 4.6 kb mRNAs are missing (Fig. 6a, lane 4).

### ***Ank3 Is the Major Ankyrin in Kidney***

No Ank1 or Ank2 is detected in mouse kidney mRNA by northern hybridization under conditions where Ank3 gives a strong signal (Fig. 6e). With prolonged exposure faint bands of ~7 kb are barely discernable above background in the Ank1 and Ank2 lanes (e.g., Fig. 6e, lane 3). Whether these are true signals or cross-hybridization with Ank3 remains to be determined.



**Figure 6.** Expression of Ankle3 in mouse tissues. (a) Northern blots of kidney Ankle3 transcripts using domain-specific hybridization probes. Each lane contains 2  $\mu$ g normal mouse kidney mRNA. Lines between lanes indicate corresponding mRNAs. The arrows in lane 1 indicate two mRNAs of 7.5 and 6.9 kb (mRNA sizes estimated relative to 18S and 28S ribosomal RNAs). The arrow in lane 2 is at  $\sim$ 6.3 kb. The probes used in each lane are as follows. Lane 1: probe 2, repeat domain-specific. Lane 2: probe 1, regulatory domain-specific. Lane 3: probe 3, specific for the unique 5' untranslated sequence of the Ankle3 clones that lack the entire repeat domain. Lane 4: probe 4, corresponding to insert C, the alternatively spliced sequence in the regulatory domain. (b) Expression of Ankle3 in normal mouse skin (lane 1, 2.5  $\mu$ g mRNA) and brain (lane 2, 2.0  $\mu$ g mRNA). The blots were hybridized with PCR1, specific to the spectrin-binding domain. Comparative experiments using several tissues reveal that PCR1 hybridizes to the same pattern of mRNAs as probe 1 (not

### *Ankle3* mRNAs Are Widely Distributed in Mouse Tissues and Exist in Many Isoforms

In addition to kidney, Ankle3 was detected in mRNA from skin, brain, lung, testis, intestine, heart, and liver by northern hybridization (Fig. 6, b–d). It was not detected in normal mouse spleen (Fig. 6 c, lane 2), in reticulocytes or spleen from mice with a phenylhydrazine-induced hemolytic anemia (not shown), in 16 d fetal liver erythroid precursor cells (not shown), or in the cultured lymphocyte cell lines JY and Jurkat (not shown).

In skin, lung, and testis, the overall pattern of Ankle3 expression is similar to that of the kidney; at least one major transcript at  $\sim$ 7.0 kb is present, there is a broad band, which potentially encompasses several mRNAs, stretching from  $\sim$ 6.3 to  $\sim$ 5.7 kb, and some smaller mRNA species ( $\sim$ 5.0 kb) are evident (Fig. 6, b and c). The  $\sim$ 7.0-kb mRNA predominates in cardiac muscle, but three additional discrete mRNAs (6.3, 6.0, and 5.6 kb) are also expressed (Fig. 6 d, lane 4).

In contrast, in the liver and intestine a 5.5–6.3-kb cluster of transcripts make up the major mRNAs (Fig. 6 d); little or no expression of the larger spliceforms is seen. Brain, on the other hand, contains only large Ankle3 transcripts:  $\sim$ 13,  $\sim$ 10 and  $\sim$ 7.0 kb (Fig. 6, b and c). The 5.7–6.3-kb mRNAs and other small species are not detected.

### *Immunoblots Confirm the Existence of Multiple Ankle3 Isoforms in Different Tissues*

The Northern analyses indicate Ankle3 is widely distributed in mouse tissues and multiple protein isoforms exist. Using an antibody raised in rabbits to a GST/Ankle3 regulatory domain fusion protein (antiAnkle3–R1), multiple Ankle3 protein isoforms are detected by Western blotting of crude kidney, brain, liver and testis membranes (Fig. 7 a, lanes 1

shown). In the skin, at least one transcript at approximately 6.9 kb (arrow) is present in addition to mRNAs extending from  $\sim$ 6.3–5.7 kb and a smaller 4.7-kb species. In the brain, major transcripts of  $\sim$ 13,  $\sim$ 10, and  $\sim$ 7 kb are present. (c) Expression of Ankle3 in normal mouse brain (lane 1), spleen (lane 2), lung (lane 3), and testis (lane 4). Each lane contains 2  $\mu$ g mRNA. The arrows are at 13 and 7 kb. The blot was hybridized with a 2.8-kb fragment of clone pA3-2 that included all of pA3-2 except the 5' sequences corresponding to probe 3. This corresponds to the entire spectrin-binding domain and most of the regulatory domain. (d) Expression of Ankle3 in intestine (lane 1, 5  $\mu$ g mRNA), kidney (lane 2, 1  $\mu$ g mRNA), liver (lane 3, 5  $\mu$ g mRNA), and heart (lane 4, 1  $\mu$ g mRNA) using PCR1 as the hybridization probe. Arrows indicate 7- and 6.3-kb mRNAs. (e) Comparison of Ankle1, Ankle2, and Ankle3 expression in the kidney. Each lane contains 2  $\mu$ g mouse kidney mRNA. Lane 1 was probed with Ankle3 probe PCR1. Lane 2 was probed with a previously described (55) 4.6-kb mouse Ankle1 cDNA. Both lanes were exposed for 22 h at  $-80^{\circ}\text{C}$  with two intensifying screens. Lane 3 is a 3-d exposure of lane 2 and shows a faint band at  $\sim$ 6.9 kb. Lane 4 was probed with a 260-bp mouse Ankle2 RT-PCR product, which was amplified from mouse brain cDNA with the same primers used to obtain PCR1. It was exposed for 22 h at  $-80^{\circ}\text{C}$ . The 3-d exposure of lane 4 also showed a very faint band at  $\sim$ 7 kb but the dark background prevented a satisfactory photograph. Note that Ankle1 and Ankle2 mRNAs are barely detectable in mouse kidney by northern analysis, even with lengthy exposure times.



to 4). In the kidney, two closely spaced polypeptides of 215 and 200 kD and single bands at 170, 120, and 105 kD are observed when blots are probed with the antibody in the presence of a 200-fold excess of bacterially expressed GST protein. All five bands disappear when the antibody reaction is performed in the presence of a 200-fold excess of the GST/Ank3 fusion protein, indicating they are all Ank3 specific. In addition, the antibody does not cross-react with Ank1 or Ank2. It does not react with Ank1 (or other proteins) in red cell ghosts (data not shown), and it does not detect Ank2 on neuronal cell bodies or dendrites (see later section on Immunocytochemistry).

Multiple Ank3 isoforms are similarly detected in crude brain membranes (Fig. 7 a, lane 2), including a predominant polypeptide of 215 kD and minor isoforms of 180, 160, 145, 135, 120, and 105 kD. In testis and liver crude membranes, small amounts of the 120- and 105-kD isoforms are found (Fig. 7 b, lanes 3 and 4). The 105-kD isoform is the major species observed in crude platelet membranes (not shown).

### The B Insert is Contained in a Single 170 kD Isoform

When antibody raised to a peptide sequence within the alternatively spliced B insert (antiAnk3-B) is used as the probe, a 170-kD isoform is present in crude membranes from kidney, liver, and testis but not brain (Fig. 7 b). It is also observed in platelet membranes (not shown). In the kidney it co-migrates with the 170-kD peptide detected with the Ank3 regulatory domain-specific antibody (antiAnk3-R1). This antiserum does not detect the 170-kD isoform in testis and liver (Fig. 7 b), but a companion antiserum (antiAnk3-R2), raised against the same GST/Ank3 regulatory domain fusion protein, does (not shown). We conclude that the B insert is expressed in a single isoform of 170 kD, and that it is present in kidney, testis, liver, and platelet membranes, but not in membranes prepared from brain.


### Immunocytochemistry

We performed immunocytochemical staining of a variety of mouse tissues using affinity purified antiAnk3-R1, prepared against the GST/Ank3 regulatory domain fusion protein. In general, Ank3 is present in epithelial tissues, muscles, and axons (Figs. 8 to 10).

### Epithelial Tissues

**Skin.** Intense staining is seen in the epithelium of the skin (Fig. 8, a and c), including that lining the sweat glands and hair follicles (Fig. 8 a, arrow).

**Lung.** Intense staining is also seen in the epithelium of the lung airways, where an *apical-lateral* concentration of reaction product is apparent (arrows) in addition to significant cytoplasmic staining (Fig. 8 d). The walls of the lung respiratory passages (alveoli) are negative. A subset of lung interstitial cells is clearly positive (Fig. 8 f, arrow). The identity of these cells is uncertain. The most likely possibility is lung macrophages, since the cells resemble macrophages and both peritoneal and bone marrow macrophages contain Ank3 (Hoock, T. C., L. L. Peters, and S. E. Lux. 1994. *Mol. Biol. Cell.* 5[Suppl]:45a.)












**Figure 7.** Western blots of membranes from various mouse tissues. (a) Crude membranes from normal mouse kidney (lane 1), brain (lane 2), testis (lane 3), and liver (lane 4) probed with antiAnk3-R1, an antibody raised to a glutathione-S-transferase (GST/Ank3 fusion protein). When probed with the same antibody in the presence of a 200-fold molar excess of purified GST/Ank3 fusion protein, the immunoreactive species indicated by the arrows were no longer detected, indicating that these are Ank3 specific isoforms. In kidney, five isoforms are present: a doublet of 215/200 kD (top arrow, lane 1) and three smaller isoforms of 170, 120, and 105 kD. In the brain, the 215-kD isoform predominates. Smaller amounts of 180-, 160-, 145-, 135-, 120- and 105-kD species are also detected. In testis, the major isoform is 120 kD. Small amounts of the 105-kD isoform are also observed. In liver, the 120- and 105-kD isoforms are present at barely detectable levels. The prominent band at 70 kD is nonspecific (NS) as it is seen even in the presence of excess GST/Ank3 fusion protein. (b) Crude normal mouse membranes from testis (lane 1), liver (lane 2), kidney (lane 3), and brain (lane 4) probed with antiAnk3-B, a peptide antibody directed against the B insert. A 170-kD isoform (arrow) is present in all but the brain membranes and is not detected when pre-immune serum is used in place of the antibody.

**Intestine.** A diffuse (cytoplasmic) Ank3 staining pattern is seen in the intestinal absorptive epithelium (Fig. 8, g and i). Interestingly, there is significantly less intense staining of epithelial cells in the crypts as compared to the villi (Fig. 8 g), which suggests that Ank3 is a marker of intestinal epithelial differentiation and maturation. In addition, the intestinal smooth muscle is positive for Ank3, as are nerve ganglia (Fig. 8 g, arrow). In contrast, the connective tissue elements in the lamina propria do not stain.

**Pancreas.** In the pancreas, apical staining of acinar cells (arrow, Fig. 9 c) and intense staining of the epithelial lining of the ducts (arrow) is apparent.

**Liver.** Ank3 immunoreactivity is weak in the liver; only a faint diffuse staining pattern is observed (not shown).

**Kidney.** Intense Ank3 immunoreactivity is seen in the kidney (Fig. 10, d-i). In the cortex, the macula densa (Fig. 10 d, left arrow), distal convoluted tubule, and cortical collecting ducts (Fig. 10 d, right arrow) are strongly positive,





particularly the basal-lateral membranes. The proximal convoluted tubules (*P*, Fig. 10 *d*) are less reactive and the stain is more diffusely distributed, perhaps due to the extensive membrane interdigitations that characterize these cells. The glomeruli (*G*, Fig. 10 *d*) do not stain. In the medulla, the descending and ascending thin limbs of the loop of Henle are negative, while the thick ascending limb is positive (Fig. 10 *g*, lower arrow). The outer medullary collecting ducts also stain intensely (Fig. 10, *e* and *f*), but Ank3 immunoreactivity falls dramatically in the inner medullary collecting ducts (Fig. 10, *g* and *h*). A strong basal-lateral concentration of immunoreactivity can be seen in the thick ascending limbs and outer medullary collecting ducts (Fig. 10, *e* and *g*). The epithelium of the renal papilla and ureter is also strongly positive (not shown).

### Muscle

Cardiac muscle (Fig. 9 *e*), skeletal muscle underlying the skin (Fig. 9 *f*), and smooth muscle in the intestine (Fig. 8 *g*) are all Ank3 immunoreactive. In the heart, the intercalated discs (arrows, Fig. 9 *e*) are clearly positive. Skeletal muscle shows a striated pattern that is consistent with localization at the transverse tubular membrane (26, 42).

### Neural Tissues

In neural tissue, the axons of outer granular and pyramidal layers of the cerebral cortex and the hippocampus (not shown) are positive, particularly the initial segments (Fig. 10 *a*, arrow). Although it is difficult to discern at this magnification, the cell bodies and dendrites appear negative. [Ank2 is located in neuronal cell bodies and dendrites (35)]. The axons of cerebellar Purkinje cells are also positive (Fig. 10 *b*, arrow) and Purkinje cell bodies and dendrites are negative. It is noteworthy that in sections of the cerebellum stained with high concentrations of the Ank3 antiserum (1:25–1:50 dilution of antiAnk3-R1 vs the 1:100–1:250 dilution used in all other experiments), diffuse staining of the molecular layer of the cerebellum occurred, which resulted in visible outlining of the unstained Purkinje cell dendritic trees (not shown). Hence, it is clear that Purkinje cell dendrites do not contain Ank3 protein. However, it is difficult to be certain unmyelinated axons of the molecular layer of the cerebellum are really Ank3 positive, because of the high concentration of antibody required to stain this area. As noted earlier, peripheral nerves (Fig. 8 *g*, arrow) also stain for Ank3.

### Other Tissues

**Leydig Cells.** In the testis, discrete areas within the cytoplasm of the interstitial (Leydig) cells are intensely positive (Fig. 9 *a*, middle and right arrows), while the Sertoli cells and seminiferous tubules stain very weakly or not at all.

**Megakaryocytes.** Although the majority of the cells in the spleen do not contain immunoreactive Ank3, particularly lymphocytes and reticuloendothelial cells, megakaryocytes are diffusely stained (Fig. 9 *h*, arrows).









### Discussion

#### *Ank3 Is the Major Ankyrin in the Kidney and Other Epithelia and Is Probably Involved in the Targeting/Maintenance of Na/K-ATPase and Other Proteins in Plasma Membranes*

Recent evidence shows that many integral membrane transporters and adhesive proteins bind ankyrins. The undoubtedly incomplete list already includes the  $\alpha$  subunit of Na/K-ATPase in renal tubules (20, 50), intestinal epithelium (22), retinal pigment epithelium (30), choroid plexus (47), and brain (58); the voltage-dependent Na channel in neurons (61) and at the neuromuscular junction (25); the amiloride-sensitive Na channel in the kidney (60); the Na/Ca exchanger in the heart (42); the H/K-ATPase in gastric parietal cells (59); the hyaluronic acid receptor (CD44) (43) and inositol 1,4,5-triphosphate (IP<sub>3</sub>) receptor (11) in lymphocytes; a group of neurofascin/L1-like putative cell adhesion molecules in the brain (17); and, of course, the Cl/HCO<sub>3</sub>-anion exchanger (AE1, band 3) in erythrocytes (7). Ankyrins also bind a related anion exchanger (AE3) in the brain (48), and probably bind a shortened isoform of AE1 in the intercalated cells of the renal collecting duct (23). In all well studied cases, the integral membrane proteins bind to part of the ankyrin repeat domain and are in turn linked to the spectrin/fodrin-based membrane skeleton. These interactions appear to play a role in establishing and/or maintaining a polarized distribution of the ligands in the membranes of non-erythroid cells (22, 23, 25, 30, 31, 47, 49, 50, 60, 61).

Ank1 and Ank2 bind to many of the proteins listed above in *in vitro* binding assays, but are unlikely to do so *in vivo* because they are expressed in different tissues. Ank1 is found in erythroid cells (53, 54), myocytes (9), en-

**Figure 8.** Immunocytochemical detection of Ank3 in mouse skin, lung, and intestine. In this and subsequent figures, red reaction product indicates the presence of Ank3 protein. The primary antibody is affinity purified antiAnk3-R1. Sections incubated in the absence of primary antibody serve as controls. All sections are counterstained with hematoxylin. (*a*) Skin. A positive reaction is seen in epithelial cells (arrow), including the epithelial cells lining the hair follicles, sebaceous glands and sweat glands. (*b*) Skin control. (*c*) High magnification of the skin showing intense Ank3 staining in all but the outermost, cornified layers of the epithelium. (*d*) Lung. Intense Ank3 reaction product is present in the epithelial cells of the conducting airways, where an apical-lateral concentration is observed (arrows). Positive staining is also seen in the smooth muscle layers (right). (*e*) Lung control. (*f*) High magnification of the lung showing an Ank3 immunoreactive interstitial cell (arrow), probably a macrophage, next to, but not abutting, alveolar airspaces. (*g*) Intestine. Diffuse Ank3 staining is present in the absorptive epithelia (*E*) of the intestinal villi. Within the intestinal crypts (*C*), less intense staining is seen. The smooth muscle (*SM*) of the muscularis layer is positive, and a nerve plexus between the muscle layers is intensely positive (arrow-head). (*h*) Intestine control. (*i*) High magnification of a portion of an intestinal villus showing the diffusely stained absorptive epithelium (*E*). Connective tissue components of the lamina propria (*Lp*) are negative. Bar, 10  $\mu$ m.



dothelial cells (Lux, S. E., unpublished data), cerebellar and spinal cord neurons (9, 35, 54), and possibly hepatocytes (52). Ank2 is limited to neurons and glia (12, 35, 52, 54). In adult animals both ankyrins are localized to neuronal cell bodies and dendrites. Fetal mice and rats express a giant isoform of Ank2 that is found in unmyelinated axons, but this protein disappears within a few days of birth. They also express an isoform of Ank2 in fetal liver precursors (53).

Numerous studies have identified "ankyrins" in other tissues using antibodies raised to Ank1 or Ank2 (4, 5, 14, 15, 22, 23, 25, 26, 29, 34, 42, 60). However, in all cases the antibody was raised to whole Ank1 or Ank2 (8, 15) or to their conserved portions (the repeat and spectrin binding domains) (6), and presumably lacked specificity. In many of these studies the problem of specificity was accentuated by using an antiserum raised to an ankyrin of one species to probe tissues of another species, by immunizing with SDS-denatured proteins, or by using affinity chromatography to concentrate cross-reacting antibodies. For example, in one case (14) an antibody to pig brain ankyrin (Ank2) was affinity purified on a column containing bovine brain ankyrin, producing a reagent that reacted with all cells of the rat kidney. More recent surveys of ankyrin expression, using specific antibodies to Ank1 (52) or Ank2 (36, 52), show a much more restricted distribution, consistent with the expression of Ank1 and Ank2 detected by northern blotting (9, 52, 54). In particular the kidney does not react significantly with such sera (52).

These studies indicate that additional ankyrins must exist in cells or sites that lack Ank1 or Ank2 but contain immunoreactive molecules. Ank3 is one such ankyrin. It is the major and possibly the only ankyrin in the kidney and other epithelial tissues, the major axonal ankyrin in adult neurons, and probably the major ankyrin in muscle. It is also found in some specialized cells, including megakaryocytes, macrophages, and the interstitial (Leydig) cells of the testis.

In the kidney the distribution of Ank3 (Fig. 10) correlates very closely with the activity of Na/K-ATPase in various segments of the nephron (33). Both proteins are expressed in the proximal convoluted tubule, the thick ascending limb of the loop of Henle, the distal convoluted tubule, and the collecting duct, and neither protein is detectable in the thin limbs of the loop of Henle (Fig. 10) (Piepenhagen, P.A., and W.J. Nelson. 1994. *Mol. Biol. Cell.* 5(Suppl.):367a). Na/K-ATPase is localized to the basal-lateral surfaces of the epithelial cells in these segments and, where its location can be discerned, Ank3 also has a basal-lateral distribution. Given these facts, and the fact that Na/K-ATPase can be isolated from kidney complexed with an ankyrin and fodrin (49-51), it is very likely

that Ank3 is involved in the targeting/maintenance of Na/K-ATPase within plasma membrane domains in epithelial cells, and perhaps in other cells. Based on location, other ankyrin-binding molecules that may serve as ligands for Ank3 include the amiloride-sensitive and voltage-gated Na-channels, the H/K-ATPase, the Na/Ca exchanger, Cl/HCO<sub>3</sub> exchangers, and members of the neurofascin/L1-like family of cell adhesion molecules.

### *Some Forms of Ank3 Lack the Repeat Domain*


Ank3 exists in diverse forms. In the kidney the transcripts can be subdivided into four groups: two relatively discrete RNAs of ~7.5- and 6.9-kb, at least one RNA at 6.3 kb, a broad band of about 5.7 kb, and minor bands of 5.1 and 4.6 kb.

The 6.9- and 7.5-kb species ("Ank3-7kb") are the only ones that are labeled by probes to all three domains, including the repeat domain (Fig. 6 a, lane 1). Several observations suggest these two transcripts encode full length kidney Ank3 with or without insert C (an acidic sequence, located in the regulatory domain that is analogous to the "2.1 insert" of Ank1 [45]). PCR products that differ by ~0.6 kb, the size of insert C, are observed when the entire coding sequence of Ank3-7kb is amplified (data not shown) and two proteins (215 and 200 kD) close to the expected sizes (214 and 193 kD) are detected on immunoblots (Fig. 7 a, lane 1). However the situation seems to be more complicated since the 6.9- and 7.5-kb transcripts both hybridize to a probe from insert C (Fig. 6 a, lane 4). Further investigations are required.

In contrast, the 6.3- and 5.7-kb RNAs lack the repeat domain and are tentatively classified as variants of "Ank3-5kb". They fail to hybridize to probes from the repeat domain and they all contain the unique 5' untranslated region found in cDNA clones in which the repeat domain is missing (Fig. 6 a, lane 3). They appear to encode a protein containing just the spectrin-binding and regulatory domains, with (6.3 kb) or without (5.7 kb) insert C. PCR surveys reveal the expected products and, as anticipated, a probe from insert C fails to hybridize to the 5.7-kb band (Fig. 6 a, lane 4). More importantly, two proteins (120 and 105 kD) very close to the predicted sizes (121 and 100 kD) are easily detected in crude renal membranes, and in fact are the major protein species (Fig. 7 a, lane 1). This strongly suggests that the truncated Ank3-5kb protein is actually synthesized, although additional evidence is needed to formally prove this point. Unfortunately, attempts to prepare an antibody specific to the six unshared NH<sub>2</sub>-terminal amino acids of Ank3-5kb, or to isolate and sequence the NH<sub>2</sub>-terminal ends of the 120- and 105-kD proteins have so far been unsuccessful.

*Figure 9.* Immunocytochemical detection of Ank3 in mouse testis, pancreas, muscle, and spleen. (a) Testis. Large cytoplasmic inclusions containing abundant Ank3 are present within the testosterone-secreting interstitial cells of Leydig (*middle and right arrows*). Weak, diffuse Ank3 reactivity is seen in the rest of the cytoplasm. A portion of a seminiferous tubule is seen on the left. These stain very weakly or not at all. No Ank3 staining is seen in the endothelial lining of small blood vessels (*top left arrow*). (b) Testis control. (c) Pancreas. Acinar cells show apical staining for Ank3 (*lower arrow*). Epithelial cells lining the ducts are strongly positive (*upper arrow*). (d) Pancreas control. (e) Heart. Ank3 is present throughout cardiac muscle fibers and is concentrated at intercalated discs (*arrows*). (f) Skeletal muscle. Skeletal muscle of the skin is Ank3 immunoreactive, while the surrounding connective tissue is negative. (g) Skeletal muscle control. (h) Spleen. Megakaryocytes (*arrows*) show diffuse Ank3 staining. (i) Spleen control. Bar, 10  $\mu$ m.





**Figure 10.** Immunocytochemical detection of Ank3 in mouse brain and kidney. (a) Cerebral cortex. Axon initial segments (*arrow*) are positive for Ank3. (b) Cerebellum. The molecular layer (*M*) is shown at top and the granule cell layer (*G*) is at the bottom. The unmyelinated neurons of the molecular layer appear negative while the axons of the Purkinje cells (*arrow*) are positive. (c) Brain (cerebral cortex) control. (d) Kidney cortex. Intense, basal-lateral Ank3 staining is seen in the macula densa (*left arrow*), distal convoluted tubules, and cortical collecting ducts (*right arrow*). Proximal convoluted tubules (*P*) show weaker and more diffuse Ank3 staining. A glomerulus (*G*) is negative. (e and f) Outer medullary collecting ducts show strong basal-lateral concentration of Ank3. (g) The junction of the outer and inner medulla. The epithelial cells of a thick ascending limb (*lower arrow*) and an outer medullary collecting duct (*upper arrow*) stain intensely for Ank3, while the inner medullary collecting ducts, at the bottom, are weakly stained. (h) High magnification photograph showing the abrupt transition (*arrow*) from heavy to light Ank3 staining of collecting ducts at the junction of the outer and inner medulla. (i) Kidney control. Bar, 10  $\mu\text{m}$ .

The minor 5.1- and 4.6-kb mRNAs also lack the repeat domain and seem to differ by the presence or absence of insert C (Fig. 6 a, lane 4); however, it is not clear whether they are translated into stable proteins.

The fifth Ank3 protein in kidney, the 170-kD isoform, is more mysterious. This is the only Ank3 species that contains the B insert. Since it is detected by antiAnk3-R1, which was made to a unique sequence near the COOH terminus of the regulatory domain, it must also contain sequences from that region. It is not clear what other parts of Ank3 are present in this isoform. The size of the related mRNA transcript is also unknown. However, it should be possible to use an antibody to the B insert to see which cells in the kidney express this protein and perhaps discover its ligands.

### **The Truncated Ank3-5kb Protein May be Associated with Cytoplasmic Structures**

It is notable that the 6.3/5.7 kb Ank3 RNAs and/or the presumptively related 120/105-kD proteins are the only forms of Ank3 detectable in intestine, testis, and liver (Figs. 6 and 7). In these tissues immunoreactivity is concentrated in the cytoplasm and is not evidently associated with the membrane (e.g., see Fig. 8, *h* and *i*). In contrast, in tissues containing the ~7-kb forms of Ank3, such as kidney, lung, heart and brain (Figs. 6 and 7), plasma membrane staining is observed, often in a polarized distribution (e.g., Fig. 8 *d* or Fig. 10, *e* and *f*). The observations suggest that the repeat domain is required to attach Ank3 to its integral membrane ligands and, in its absence, that the protein remains in the cytoplasm or attaches to cytoplasmic structures. Preliminary studies of Ank3 in mouse bone marrow macrophages support this concept. The macrophages only have ~5.0- and ~3.6-kb Ank3 transcripts, neither of which contains the repeat domain. The related proteins (120 and 105 kD) are associated solely with the membrane of phase dense, late lysosomal vesicles, and not with the plasma membrane (Hooek, T. C., L. L. Peters, and S. E. Lux. 1994. *Mol. Biol. Cell.* 5[Suppl]:45a). These preliminary observations suggest that ankyrins lacking the repeat domain may play a role in intracellular vesicle stabilization, sorting or targeting, or have other still undiscovered functions.

The authors especially thank Tom Hooek for assisting with characterization of the Ank3-R1 antibody, and Bill Harris and Lynn Reid for help in interpreting tissue immunocytochemistry.

This work was supported by National Institutes of Health grants HL32262 (S. E. Lux), DK34083 (S. E. Lux) and RR01183 (E. M. Eicher), and National Science Foundation grant BNS-9112820 (A. J. Otsuka).

Received for publication 25 January 1995 and in revised form 7 April 1995.

### **References**

1. 1994 Chromosome Committee Data. 1995. Encyclopedia of the Mouse Genome, Mouse Informatics Project. The Jackson Laboratory, Bar Harbor, ME. World Wide Web (URL: <http://www.informatics.jax.org>).
2. Barnes, W. M. 1994. PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. *Proc. Natl. Acad. Sci. USA.* 91:2216-2220.
3. Bel Sal G., G. Manfioletti, and C. Schneider. 1989. The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemids, phages or plasmids suitable for sequencing. *BioTechniques.* 7:514-520.
4. Bennett, V. 1979. Immunoreactive forms of human erythrocyte ankyrin are

- present in diverse cells and tissues. *Nature (Lond.).* 281:597-599.
5. Bennett, V., and J. Davis. 1981. Erythrocyte ankyrin: Immunoreactive analogues are associated with mitotic structures in cultured cells and with microtubules in brain. *Proc. Natl. Acad. Sci. USA.* 78:7550-7554.
6. Bennett, V., and P. J. Stenbuck. 1979. Identification and partial purification of ankyrin, the high affinity membrane attachment site for human erythrocyte spectrin. *J. Biol. Chem.* 254:2533-2541.
7. Bennett, V., and P. J. Stenbuck. 1980. Association between ankyrin and the cytoplasmic domain of band 3 isolated from human erythrocyte membrane. *J. Biol. Chem.* 255:6424-6432.
8. Bennett, V., J. Davis, and W. E. Fowler. 1982. Brain spectrin, a membrane-associated protein related in structure and function to erythrocyte spectrin. *Nature (Lond.).* 299:126-131.
9. Birkenmeier, C. S., R. A. White, L. L. Peters, E. J. Hall, S. E. Lux, and J. E. Barker. 1993. Complex patterns of sequence variation and multiple 5' and 3' ends are found among transcripts of the erythroid ankyrin gene. *J. Biol. Chem.* 268:9533-9540.
10. Bork, P. 1993. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile molecules that cross phyla horizontally? *Proteins.* 17:363-374.
11. Bourguignon, L. Y., H. Jin, N. Iida, N. R. Brandt, and S. H. Zhang. 1993. The involvement of ankyrin in the regulation of inositol 1,4,5-trisphosphate receptor-mediated internal  $Ca^{2+}$  release from  $Ca^{2+}$  storage vesicles in mouse T-lymphoma cells. *J. Biol. Chem.* 268:7290-7297.
12. Chan, W., E. Kordeli, and V. Bennett. 1993. 440-kD ankyrin B: Structure of the major developmentally regulated domain and selective localization in unmyelinated axons. *J. Cell Biol.* 123:1463-1473.
13. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.
14. Davis, J., L. Davis, and V. Bennett. 1989. Diversity in membrane binding sites of ankyrins. Brain ankyrin, erythrocyte ankyrin, and processed erythrocyte ankyrin associate with distinct sites in kidney microsomes. *J. Biol. Chem.* 264:6417-6426.
15. Davis, J. Q., and V. Bennett. 1984. Brain ankyrin. Purification of a 72,000 Mr spectrin-binding domain. *J. Biol. Chem.* 259:1874-1881.
16. Davis, J. Q., and V. Bennett. 1984. Brain ankyrin. A membrane-associated protein with binding sites for spectrin, tubulin, and the cytoplasmic domain of the erythrocyte anion channel. *J. Biol. Chem.* 259:13550-13559.
17. Davis, J. Q., T. McLaughlin, and V. Bennett. 1993. Ankyrin-binding proteins related to nervous system cell adhesion molecules: candidates to provide transmembrane and intercellular connections in adult brain. *J. Cell Biol.* 121:121-133.
18. Davis, L. H., and V. Bennett. 1990. Mapping the binding sites of human erythrocyte ankyrin for the anion exchanger and spectrin. *J. Biol. Chem.* 265:10589-10596.
19. Davis, L. H., J. Q. Davis, and V. Bennett. 1992. Ankyrin regulation: an alternatively spliced segment of the regulatory domain functions as an intramolecular modulator. *J. Biol. Chem.* 267:18966-18972.
20. Devarajan, P., D. A. Scaramuzzino, and J. S. Morrow. 1994. Ankyrin binds to two distinct cytoplasmic domains of Na,K-ATPase  $\alpha$  subunit. *Proc. Natl. Acad. Sci. USA.* 91:2965-2969.
21. Deveraux, J., P. Haeberli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. *Nucleic Acids Res.* 12:387-395.
22. Drenckhahn, D., and V. Bennett. 1987. Polarized distribution of Mr 210,000 and 190,000 analogs of erythrocyte ankyrin along the plasma membrane of transporting epithelia, neurons and photoreceptors. *Eur. J. Cell Biol.* 43:479-486.
23. Drenckhahn, D., K. Schluter, D. P. Allen, and V. Bennett. 1985. Colocalization of band 3 with ankyrin and spectrin at the basal membrane of intercalated cells in the rat kidney. *Science (Wash. DC).* 230:1287-1289.
24. Dubreuil, R. R., and J. Q. Yu. 1994. Ankyrin and  $\beta$ -spectrin accumulate independently of  $\alpha$ -spectrin in Drosophila. *Proc. Natl. Acad. Sci. USA.* 91:10285-10289.
25. Flucher, B., and M. Daniels. 1989. Distribution of  $Na^+$  channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein. *Neuron.* 3:163-175.
26. Flucher, B. E., M. E. Morton, S. C. Froehner, and M. P. Daniels. 1990. Localization of the  $\alpha_1$  and  $\alpha_2$  subunits of the dihydropyridine receptor and ankyrin in skeletal muscle triads. *Neuron.* 5:339-351.
27. Gallagher, P. G., W. T. Tse, A. L. Scarpa, S. E. Lux, and B. G. Forget. 1992. Large number of alternatively spliced isoforms of the regulatory region of human erythrocyte ankyrin. *Trans. Assoc. Am. Phys.* 105:268-277.
28. Georgatos, S. D., and V. T. Marchesi. 1985. The binding of vimentin to human erythrocyte membranes: a model system for the study of intermediate filament-membrane interactions. *J. Cell Biol.* 100:1955-1961.
29. Gregorio, C. C., E. A. Repasky, V. M. Fowler, and J. D. Black. 1994. Dynamic properties of ankyrin in T lymphocytes: Colocalization with spectrin and protein kinase C $\beta$ . *J. Cell Biol.* 125:345-358.
30. Gundersen, D., J. Orlowski, and E. Rodriguez-Boulan. 1991. Apical polarity of  $Na^+, K^+$ -ATPase in retinal pigment epithelium is linked to a reversal of the ankyrin-fodrin submembrane cytoskeleton. *J. Cell Biol.* 5:863-872.
31. Hammerton, R. W., K. A. Krzeminski, R. W. Mays, T. A. Ryan, D. A. Wollner, and W. J. Nelson. 1991. Mechanism for regulating cell surface

- distribution of Na<sup>+</sup>,K<sup>+</sup>-ATPase in polarized epithelial cells. *Science (Wash. DC)*. 254:847–850.
32. Kaelin, W. G., Jr., W. Krek, W. R. Sellers, J. A. DeCaprio, F. Ajchenbaum, C. S. Fuchs, T. Chittenden, Y. Li, P. J. Farnham, M. A. Blannar, D. M. Livingston, and E. K. Flemington. 1992. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. *Cell*. 70:351–364.
  33. Katz, A. I., A. Doucet, and F. Morel. 1979. Na/K-ATPase activity along the rabbit, rat, and mouse nephron. *Am. J. Physiol.* 237:F114–F120.
  34. Koob, R., M. Zimmermann, W. Schoner, and D. Drenckhahn. 1988. Colocalization and coprecipitation of ankyrin and Na<sup>+</sup>,K<sup>+</sup>-ATPase in kidney epithelial cells. *Eur. J. Cell Biol.* 45:230–237.
  35. Kordeli, E., and V. Bennett. 1991. Distinct ankyrin isoforms at neuron cell bodies and nodes of Ranvier resolved using erythrocyte ankyrin-deficient mice. *J. Cell Biol.* 114:1243–1259.
  36. Kordeli, E., J. Davis, B. Trapp, and V. Bennett. 1990. An isoform of ankyrin is localized at nodes of Ranvier in myelinated axons of central and peripheral nerves. *J. Cell Biol.* 110:1341–1352.
  37. Kordeli, E., S. Lambert, and V. Bennett. 1995. Ankyrin<sub>C</sub>: a new ankyrin gene with neural-specific isoforms localized to the axonal initial segment and node of Ranvier. *J. Biol. Chem.* 270:2352–2359.
  38. Kozak, M. 1987. An analysis of 5'-noncoding sequencing from 699 vertebrate messenger RNAs. *Nucleic Acids. Res.* 15:8125–8148.
  39. Laemmli, U. K. 1970. Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)*. 227:680–685.
  40. Lambert, S., and V. Bennett. 1993. Postmitotic expression of ankyrin<sub>R</sub> and beta<sub>2</sub>-spectrin in discrete neuronal populations of the rat brain. *J. Neurosci.* 13:3725–3735.
  41. Lambert, S., H. Yu, J. T. Prchal, J. Lawler, P. Ruff, D. Speicher, M. C. Cheung, Y. W. Kan, and J. Palek. 1990. cDNA sequence for human erythrocyte ankyrin. *Proc. Natl. Acad. Sci. USA*. 87:1730–1734.
  42. Li, Z., E. P. Burke, J. S., Frank, V. Bennett, and K. D. Philipson. 1993. The cardiac Na<sup>+</sup>-Ca<sup>2+</sup> exchanger binds to the cytoskeletal protein ankyrin. *J. Biol. Chem.* 268:11489–11491.
  43. Lokeshwar, V. B., N. Fregien, and L. Y. W. Bourguignon. 1994. Ankyrin-binding domain of CD44 (GP85) is required for the expression of hyaluronate-mediated adhesion function. *J. Cell Biol.* 126:1099–1109.
  44. Lux, S. E., and J. Palek. 1995. Disorders of the red cell membrane. R. I. Handin, S. E. Lux, T. P. Stossel, editors. *In Blood: Principles and Practice of Hematology*. Chapter 54. J. B. Lippincott, Philadelphia: 1701–1818.
  45. Lux, S. E., K. M. John, and V. Bennett. 1990. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins. *Nature (Lond.)*. 344:36–43.
  46. Lux, S. E., W. T. Tse, J. C. Menninger, K. M. John, P. Harris, O. Shalev, R. R. Chilcote, S. L. Marchesi, P. C. Watkins, V. Bennett, S. McIntosh, F. S. Collins, U. Francke, D. C. Ward, and B. G. Forget. 1990. Hereditary spherocytosis associated with deletion of the human erythrocyte ankyrin gene on chromosome 8. *Nature (Lond.)*. 345:736–739.
  47. Marrs, J. A., E. W. Napolitano, C. Murphy-Erdosh, R. W. Mays, L. F. Reichardt, and W. J. Nelson. 1993. Distinguishing roles of the membrane-cytoskeleton and cadherin mediated cell-cell adhesion in generating different Na<sup>+</sup>,K<sup>+</sup>-ATPase distributions in polarized epithelia. *J. Cell Biol.* 123:149–164.
  48. Morgans, C. W., and R. R. Kopito. 1993. Association of the brain anion exchanger, AE3, with the repeat domain of ankyrin. *J. Cell Sci.* 105:1137–1142.
  49. Nelson, W. J., E. M. Shore, A. Z. Wang, and R. W. Hammerton. 1990. Identification of a membrane-cytoskeletal complex containing the cell adhesion molecule uvomorulin (E-cadherin), ankyrin, and fodrin in Madin-Darby canine kidney epithelial cells. *J. Cell Biol.* 110:349–357.
  50. Nelson, W. J., and P. J. Veshnock. 1987. Ankyrin binding to (Na<sup>+</sup> + K<sup>+</sup>)-ATPase and the implications for the organization of membrane domains in polarized cells. *Nature (Lond.)*. 328:533–536.
  51. Nelson, W. J., and R. W. Hammerton. 1989. A membrane-cytoskeletal complex containing Na<sup>+</sup>, K<sup>+</sup>-ATPase, ankyrin, and fodrin in Madin-Darby canine kidney (MDCK) cells: implications for the biogenesis of epithelial cell polarity. *J. Cell Biol.* 108:893–902.
  52. Otto, E., M. Kunimoto, T. McLaughlin, and V. Bennett. 1991. Isolation and characterization of cDNAs encoding human brain ankyrins reveal a family of alternatively spliced genes. *J. Cell Biol.* 114:241–253.
  53. Peters, L. L., and S. E. Lux. 1993. Ankyrins: structure and function in normal cells and hereditary spherocytes. *Semin. Hematol.* 30:85–118.
  54. Peters, L. L., C. S. Birkenmeier, R. T. Bronson, R. A. White, S. E. Lux, E. Otto, V. Bennett, and J. E. Barker. 1991. Purkinje cell degeneration associated with erythroid ankyrin deficiency in nb/nb mice. *J. Cell Biol.* 114:1233–1241.
  55. Platt, O. S., S. E. Lux, and J. F. Falcone. 1993. A highly conserved region of human erythrocyte ankyrin contains the capacity to bind spectrin. *J. Biol. Chem.* 268:24421–24426.
  56. Rowe, L. B., J. H. Nadeau, R. Turner, W. N. Frankel, V. A. Letts, J. T. Eppig, M. S. H. Ko, S. J. Thurton, and E. H. Birkenmeier. 1994. Maps from two interspecific backcross DNA panels available as a community genetic mapping resource. *Mammalian Genome*. 5:253–274.
  57. Sambrook, J., T. Fritsch, and T. Maniatis. 1989. *Molecular Cloning: A Laboratory Manual*. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  58. Shibayama, Y., K. Nakaya, and Y. Nakamura. 1993. Differential binding activity of erythrocyte ankyrin to the alpha-subunits of Na<sup>+</sup>,K<sup>+</sup>-ATPases from rat cerebral and axonal membrane. *Cell Struct. Funct.* 18:79–85.
  59. Smith, P. R., A. L. Bradford, E. H. Joe, K. J. Angelides, D. J. Benos, and G. Saccomani. 1993. Gastric parietal cell H<sup>(+)</sup>-K<sup>(+)</sup>-ATPase microsomes are associated with isoforms of ankyrin and spectrin. *Am. J. Physiol.* 264:C63–C70.
  60. Smith, P. R., G. Saccomani, E. H. Joe, K. J. Angelides, and D. J. Benos. 1991. Amiloride-sensitive sodium channel is linked to the cytoskeleton in renal epithelial cells. *Proc. Natl. Acad. Sci. USA*. 88:6971–6975.
  61. Srinivasan, Y., L. Elmer, J. Davis, V. Bennett, and K. Angelides. 1988. Ankyrin and spectrin associate with voltage-dependent sodium channels in brain. *Nature (Lond.)*. 333:177–180.
  62. Tse, W. T., J. C. Menninger, T. L. Yang-Feng, U. Francke, K. E. Sahr, S. E. Lux, D. C. Ward, and B. G. Forget. 1991. Isolation and chromosomal localization of a novel non-erythroid ankyrin gene. *Genomics*. 10:858–866.
  63. Wang, R. F., W. W. Cao, and M. G. Johnson. 1992. A simplified, single tube, single buffer system for RNA-PCR. *BioTechniques*. 12:702–704.
  64. White, R. A., C. S. Birkenmeier, L. L. Peters, J. S. Barker, and S. E. Lux. 1992. Murine erythrocyte ankyrin cDNA: Highly conserved regions of the regulatory domain. *Mammalian Genome*. 3:281–285.
  65. White, R. A., C. S. Birkenmeier, S. E. Lux, and J. E. Barker. 1990. Ankyrin and the hemolytic anemia mutation, nb, map to mouse chromosome 8: Presence of the nb allele is associated with a truncated erythrocyte ankyrin. *Proc. Natl. Acad. Sci. USA*. 87:3117–3121.